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Abstract 
 
 
South Africa (SA) is burdened with one of the highest tuberculosis (TB) infection rates 
worldwide. The dual epidemic of HIV and MDR- and extensively drug-resistant (XDR) -TB 
outbreaks prompted the World Health Organisation to call for a new rapid molecular 
diagnostics tool(s). To curb the spread of drug-resistant TB, SA introduced genotypic Hain 
MTBDRplus line probe assays (Hain LPA) for the routine rapid diagnosis of MDR-TB. This 
study aimed to determine the frequency, geographic distribution and genetic basis for 
phenotypic and genotypic drug susceptibility testing (DST) discordant findings. The cultures 
used in this study were isolated during the period June 2007- July 2008 from Western Cape, 
Gauteng, KwaZulu-Natal, and Northern Cape. A total of 118 comparable MGIT and Hain 
LPA DST were obtained with 41 isolates verified to be discordant. The predominant families 
were the LAM, T, X and, S. Hain LPA failed to identify INH resistance (R) in 46.3% (19/41) 
of isolates with MIC‟s supporting the phenotypic resistance. Genotypic RIF-R was shown in 
31.7% (13/41) of isolates which was not expressed phenotypically but interestingly the 
MIC‟s favour the LPA resistance. Sequencing analysis of the rpoB gene region identified 
new mutations; Leu458Pro, Leu436Pro, and Asp441Gly, associated with missing wildtypes. 
For INH, the katG and inhA gene regions were sequenced. Mutations at codon Gly213Val, 
Pro232Lys, Lys254Asn, and Ser259Asn were detected in katG and a variety found in inhA. 
These mutations have not been previously reported neither are they incorporated on the Hain 
LPA strips.  Detailed knowledge of the frequency distribution of resistance-linked mutations 
and associated MICs in different regions of SA, could facilitate understanding of the 
limitations of current molecular tests and inform testing algorithms. These findings impact on 
the use of new molecular diagnostics as well as epidemiological monitoring of drug-resistant 
strains.  
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CHAPTER 1 
 
1 LITERATURE REVIEW 
 
1.1 Introduction 
 
Tuberculosis (TB) is a chronic infectious airborne disease caused by the tubercle bacillus M. 
tuberculosis (Cole et al, 1998). TB infections are characterised by the growth of rod-shaped 
bundles of the M. tuberculosis bacteria which in susceptible animals, including humans 
produce microscopic “tubercles” consisting of chronic granulomas, some with caseous 
necrosis. Lung tissue is frequently infected, but other parts of the body can be involved 
(Knechel, 2009). In 2009, 9.4 million new TB cases, including the HIV infected population, 
were recorded.  
 
Although one-third of the world‟s population is infected by M. tuberculosis, only 
approximately 5-10% of the infected population who are HIV uninfected will develop TB at 
some stage in their life. HIV and TB co-infected populations are more like to develop TB. 
(WHO, 2010). Factors that contribute to the development of tuberculosis disease are complex 
and not completely understood but suppression of cell-mediated immunity plays a key role 
(Caws et al, 2008).  
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1.2 Classification of the Genus Mycobacterium 
 
Mycobacterium tuberculosis, the causative agent of TB, was first discovered by Robert Koch 
in 1882 (Grange, 2009). In 1896, Lehmann and Neumann classified the tubercle bacillus 
under the binomial genus plus species term Mycobacterium tuberculosis (Grange, 2009). The 
Mycobacterium genus includes more than 120 different species and is classified under the 
order of Actinomycetalis, with its own family, Mycobacteriaceae. Within the Mycobacterium 
genus, the pathogens known to cause serious diseases in mammals are those causing 
tuberculosis (Mycobacterium tuberculosis) and leprosy (Mycobacterium leprae) (Ryan et al, 
2010). The genus name is derived from the Greek word, „myces-‟ which means “fungus” and 
relates to the mould-like manner in which mycobacteria grow in liquid culture (Kerr, 2004). 
There are two distinct subgroups in the Mycobacterium genus: slow growers and rapid 
growers (Tortoli, 2003) with the latter being closely related to the Nocardia genus. The slow 
growing population include members of the Mycobacterium tuberculosis Complex (MTBC) 
which are the causative agents of tuberculosis in animals and humans (Ryan et al, 2010). 
Species included in the MTBC are; M. tuberculosis (the major cause of human tuberculosis), 
M. bovis (cattle, deer), M. africanum (human), M. canetti (human), M. caprae (goats), M. 
microti (vole), M. pinnipedii (seal) (Grange 2009). The MTBC species are grouped by their 
similarity at the nucleotide level and 16S rRNA sequences but differ largely in their host 
tropisms, phenotypes and pathogenicity (Brosch et al, 2002). Rapid growers usually have two 
copies of 16S rRNA, while slow growers have only one copy (Tortoli, 2003).  
 
The clinical significance of M. tuberculosis resulted in it being selected as the type species of 
the Mycobacterium genus and, with the exception of M. leprae  and Mycobacterium ulcerans 
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the causative agent of Buruli ulcer all- other Mycobacterium species are grouped together and 
called the „non-tuberculous mycobacteria‟ (NTM) (Grange, 2009). 
 
1.3 Structure of Mycobacteria 
 
The mycobacteria are mostly straight or curved rods which are non-sporing (Knechel, 2009) 
and do not have flagellae. The morphology of mycobacteria in clinical specimens vary 
between species and are affected by exposure to antimicrobial therapy (Grange 2009). 
Mycobacteria are Gram-positive and acid-fast bacilli (AFB) (Brosch et al, 2002). The typical 
size of mycobacteria is 0.5µm by 3µm and they have a complex cell wall structure which is 
core to their survival (Knechel, 2009). The cell wall has a high lipid content which includes 
mycolic acids and a trehalose-mycolic acid component called cord factor which has been 
identified as an important virulence factor. Below the cell wall is the cell membrane which 
has two phospholipid layers (Cole et al, 1998). The innermost layer of the cell wall gives the 
bacterium its rigidity and is made up of a net-like macromolecule comprising peptidoglycan 
and long polysaccharide chains crossed linked with short four amino acid peptides (Dean et 
al, 2001). To the peptidoglycan or murein layer, mycolic acids (long chain fatty acids) are 
attached giving the thick cell wall its rigidity (Tortoli, 2003). This thick lipid wall provides a 
barrier responsible for the physiological properties of M. tuberculosis which enables it to be 
resistant to antibiotics and resistant to host defence mechanisms (Knechel, 2009). M. 
tuberculosis contains a guanine (G) + cytosine (C) - rich genome (Cole et al, 1998). 
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1.4 Growth and Metabolic Characteristics of Mycobacteria 
 
Most mycobacterial species, both slow and rapid growers are able to grow on simple media 
due to their undemanding nutritional requirements. Clinical cultivation of mycobacteria in 
laboratories is usually done on Löwenstein-Jensen (LJ) medium (Ryan, 2004). M. 
tuberculosis grows in small buff-coloured colonies resembling small cauliflowers or bread 
crumbs. It is a slow grower and takes between 6-8 weeks to produce a full lawn of growth 
(Kent et al, 1985). The commercial liquid-based mycobacterial culture system such as Becton 
Dickson BACTEC MGIT 960 system is also used and is preferred as it takes 8-12 day for 
bacterial growth instead of weeks (Whitelaw et al, 2009). 
 
1.5 Mycobacterial Antigens 
 
 Mycobacteria have a complex antigenic structure and their antigens can be divided into three 
main categories: actively secreted, cell-wall bound, and cytoplasmic. The immune system of 
infected hosts is initially exposed to the first two categories and these play important roles in 
the activation of host defence mechanisms and in pathogenesis (Grange, 2009). Soluble and 
cell-bound mycobacterial antigens have been functionally characterised and a few have been 
used for the development of diagnostic tests involving antibody or cell-mediated host 
immune responses.  
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1.6 The M. tuberculosis Genome 
 
The type strain of M. tuberculosis, H37Rv, was isolated in 1905 and is referred to as the TB 
reference strain. It is used worldwide in biomedical research applications due to its virulence 
in animal models (Cole et al, 1998). Sequenced in 1998, H37Rv genome consists of 4.4x10
6 
base pairs (bp) with about 4000 genes (Smith, 2003). The large genome is made up of 65% G 
+ C content which is relatively constant throughout indicating that it evolved with little or no 
other bacterial DNA inclusion from other genera (Grange, 2009). It is rich in repetitive DNA, 
especially with insertion sequences, new multigene families and duplicated housekeeping 
genes (Cole et al, 1998).  
 
In comparison to other bacteria, the majority of the genes are involved in lipid synthesis and 
metabolism. There are approximately 250 enzymes associated with lipid metabolism of M. 
tuberculosis (Grange, 2009). An unusual feature of the M .tuberculosis genome is the coding 
of the Pro-Glu (PG) and Pro-Pro-Glu (PPG) glycine-rich proteins (Cole et al, 1998) whose 
functions are unknown but are found in the cell membrane and cell wall. It is hypothesised 
that these proteins contribute to the antigenic variance of M. tuberculosis during infection 
(Smith, 2003). 
 
1.7 The Origins and evolution of Mycobacterium tuberculosis 
 
Evidence suggests that tuberculosis would have already infected and caused disease in human 
ancestors several thousand years (roughly 15000-20000 years) ago (Sreevatsan et al, 1997). 
Based on evidence of tuberculosis found in early hominids in East Africa during that period, 
it is suggested that tubercle bacilli emerged in Africa (Gutierrez et al, 2005; Grange, 2009).  
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The genus Mycobacterium is thought to have originated like other aerobic actimomycetes 
from soil bacteria with some species (M. tuberculosis and M. leprae) evolving to live in 
mammals (Smith, 2003). Prior to sequencing, M. tuberculosis was thought to have resulted 
from a species jump from animals to humans (Grange, 2009; Brosch et al, 2002). 
Domestication of cattle was initially presumed to have allowed the mycobacterium pathogen 
found in livestock to evolve to humans (Cole, 1998; Smith et al, 2009). Already in 1898 
small differences were observed between the tubercle bacilli isolated from humans and cattle. 
Strains recovered from cattle were referred to as bovine tubercle bacilli (M. bovis) (Grange, 
2009) and was hypothesised to be the evolutionary precursor of M. tuberculosis (Smith et al, 
2009). However, detailed genomic sequencing (Cole et al, 1998) shows a different picture.  
MTBC complex differ in phenotypic characteristics but display extreme genetic 
homogeneity, 99.95% sequence similarity (Brosch et al, 2002) with a high degree of 
conservation in their house keeping genes and no significant trace of genetic exchange among 
species. It is therefore believed that MTBC are the clonal progeny of a single ancestor 
(Gutierrez et al, 2005; Brosch et al, 2002). Research shows that the ancestral member of the 
complex, „M. prototuberculosis” is about 3 million years old. Recent studies have suggested 
that M. bovis and M. tuberculosis have evolved separately around the same time (Sreevatsan 
et al, 1997).    
 
1.8 Transmission of M. tuberculosis 
 
Although tuberculosis has afflicted humanity for centuries, it has only recently come to light 
that the disease is a result of a „transmissible airborne infection‟ (Dharmadhikari et al, 2009). 
Scientists like Aristotle believed that TB was contagious but the mechanisms of how and 
what caused the disease were not understood (Smith, 2003). Opposing theories of TB 
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transmission were entertained historically. In the Northern countries in the second half of the 
17
th
 century (Smith, 2003) a predominant dogma was that TB was a hereditary disease 
(Smith, 2003). In the 1950s, William Firth Wells and engineers conceptualised how causative  
agents of certain infectious diseases, , such as TB, might become airborne and be transmitted 
from one person to another (Dharmadhikari et al, 2009).  
 
The majority of tuberculosis infections are spread through the inhalation of small airborne 
droplet nuclei carrying the causative agent (Ryan et al, 2010). The airborne droplets are 
generated from coughing, sneezing, talking or singing of a person with pulmonary or 
laryngeal tuberculosis (Knechel, 2009). These droplets are expelled into the air (a single 
cough can produce 3000 droplet nuclei) and can remain airborne for several hours (Maher, 
2009a). The transmission of the infectious particle, less than 5µm (Maher, 2009a) in diameter 
is influenced by the virulence of the bacilli, exposure of the bacilli to UV light, degree of 
ventilation and aerosolization (Knechel, 2009). Exposure of the lungs to the M. tuberculosis 
bacilli leads to respiratory infections, however tuberculosis disease can be found in other 
organs such as the lymphatics, pleura, bones/joints or meninges and cause extrapulmonary 
tuberculosis (Dharmadhikari et al, 2009; Knechel, 2009).  
 
1.9 Epidemiology of tuberculosis 
 
Despite effective treatment, TB remains a major public health threat, causing 2-3 million 
deaths annually of which 98% are from developing countries (Arnold, 2006). This situation is 
further exacerbated by the emergence of drug-resistant strains of M.tuberculosis requiring 
prolonged, more expensive, less effective therapy. In 2009, based on infection and disease 
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prevalence surveys, surveillance systems, and death registrations (Dye et al, 2008), an 
estimated 8.7 million new TB cases were recorded, with a global incidence rate of 125 cases 
per 100 000 population (WHO, 2011). Globally there were 440 000 new MDR-TB cases 
(defined as Mycobacterium tuberculosis resistant to both INH and RIF) reported with 
150 000 deaths in 2008. In 2009, 3.3% of all new cases reported had MDR-TB, with XDR-
TB (TB resistant to flouroquinolones and at least one injectable second-line drug) been 
confirmed in 58 countries (WHO, 2010).  The bulk of the global TB burden is from South-
East Asia, African and Western Pacific regions (Figure 1.1).  
 
In 2009, an estimated 1.1 million (26%) new TB case arose in patients with HIV, with a 53% 
HIV prevalence among TB patients in the African region (WHO, 2010).  
 
 
Figure 1.1 Global TB incidence rates (WHO, Global Tuberculosis report, 2010). 
In SA, TB is a notifiable disease, with steadily increasing incidence rates recorded in the 20
th
 
century. In 2002, WHO recognised South Africa as one of the 22 high burden countries who 
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collectively contribute 80% of the epidemiological TB burden worldwide (WHO, 2010). In 
2006, the TB crisis in SA was highlighted by an outbreak in a rural hospital in KwaZulu-
Natal province with 39% (72/185) of culture-confirmed patients had MDR-TB, with 53 of 
them with XDR-TB (Gandhi et al, 2006). In 2007, TB was declared a national emergency 
(SA Department of Health, 2007). In 2008 WHO Strategic and Technical Advisory Group for 
Tuberculosis (STAG-TB) recognised the need to use molecular rapid molecular diagnostic 
tools and requested evidence for the use of LPA in low and middle income countries.  
 
Currently, WHO estimates the TB incidence rates to be 971 per 100 000 population in SA 
with the total of 405 982 cases being notified (WHO, 2011a). In addition SA has a high 
burden of drug resistant TB. MDR-TB is found in 1.8% of all new TB cases and in 6.7% of 
re-treatment cases in SA with just over 9 000 confirmed MDR-TB cases reported in SA in 
2010. (WHO, 2011a).  
 
Drug resistance develops either through acquisition or transmission. Acquired resistance 
develops spontaneously through poor adherence, inappropriate treatment or poor absorption 
of drugs. In contrast, primary resistance develops when individuals are infected with an 
already drug-resistant strain (van Rie et al, 2005).  It is important to understand the relative 
contribution of primary versus acquired drug resistance to the drug resistant TB burden in 
different communities. A central question is whether MDR-TB strains are transmissible or 
whether mutations conferring drug resistance affect the fitness of the strain by impairing 
reproductive function (Mathema et al, 2008).  Several MDR and XDR-TB outbreaks have 
been reported, suggesting that drug resistant TB strains do have the potential for transmission 
(Sacks et al, 1999; Gandhi et al, 2006).  
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1.10 Molecular epidemiology of Mycobacterium tuberculosis 
 
Molecular epidemiology is comparatively a young science aimed at addressing the 
epidemiological relationships between patients infected with TB through the association of 
the genotypes of the infecting bacteria causing disease (van der Spuy et al, 2008). It 
complements classical epidemiology by using molecular tools to track and confirm suspected 
outbreaks and transmission of different disease-causing stains over space and time (Bifani et 
al, 2002; McEvoy et al, 2009).  
 
The introduction of various molecular genotyping methods has facilitated the development of 
a new field of scientific research, known as molecular epidemiology which has greatly 
enhanced our understanding of the disease dynamics of the TB epidemic. Using genotyping 
methods such as spoligotyping or IS6110 –based restriction fragment length polymorphisms 
(RFLPs), genetically similar strains of M. tuberculosis can be classified into strain families or 
lineages such as W-Beijing or Haarlem (Mathema et al, 2008).  
 
It is strategically important for the National TB Control Programme (DoH, 2007) to know the 
relative proportion of acquired and transmitted drug resistance in clinical isolates. Clustered 
cases of TB are defined as those who have identical or closely related genotypes and reflect 
on-going transmission. In contrast epidemiologically unrelated TB cases demonstrate broad 
genotypic variability and are interpreted to reflect acquisition of drug resistance. Drug 
resistance mutations can also provide genetic markers to demonstrate clonality 
(transmission). Genotypic data only provides information about the pathogen and therefore 
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should be interpreted in conjunction with additional and epidemiologic information to inform 
the TB control program (Barnes et al, 2003). 
 
Other than from the Western Cape, there is relatively little genotypic information  available 
regarding circulating drug susceptible or resistant M. tuberculosis strains in South Africa. 
Genotyping of drug-resistant M. tuberculosis isolates collected from clinics in the Boland-
Overburg and Southern Cape-Karoo regions between January 2001 to February 2002 showed 
that four strain families were responsible for more than 70% of the drug-resistant TB in that 
area. This included the Beijing/W-like family, the IS6110 low-copy-number clade and the 
F11 and F28 families (Streicher et al, 2004). Temporal analysis indicated that the Beijing 
clade had increased significantly in comparison to other clades primarily due to R220 strain 
(Johnson et al, 2010). This correlated with a previous study that showed the Beijing clade 
was increasing significantly in the Western Cape over this time period (van der Spuy et al, 
2009). A hospital based prospective study of children with culture-confirmed tuberculosis in 
the Western Cape showed Beijing was the most prevalent genotype family, followed by 
LAM. The presence of both Beijing and Harlem genotype families was significantly 
associated with drug resistance (Marais et al, 2006). In KwaZulu-Natal (KZN) XDR-TB is 
reported to be was caused primarily by a single strain genotype with a distinct genotype by 
spoligotyping (F15/LAM4/KZN) (Pillay et al, 2007; Loerger et al, 2009).  
 
However, spoligotyping of 41 XDR-TB isolates from 7 provinces, showed high genotypic 
diversity including seven internationally recognised genotype families (Beijing family, 
Latino-American-Mediterranean family, East-African-Indian family, the T, H, S and X3 
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families). The Beijing genotype family formed the largest group (Mlambo et al, 2008). A 
recent paper by Chihota et al, reporting on genotyping of MDR-TB strains from four 
provinces in SA showed distinct strain population structures in each province with specific 
strain families showing localisation to a particular geographical region (Chihota et al, 2012). 
In addition to recognising primary transmission versus acquired drug resistance, molecular 
epidemiology and comparative genomics can explore the evolutionary origins of M. 
tuberculosis and phylogenetic relationships between different strain families and distinguish 
exogenous reinfection from endogenous reactivation and cases of recurrent TB, thus 
enhancing our understanding of the epidemic (Mathema et al, 2008).  
 
1.11 Pathogenesis and Virulence of Tuberculosis 
 
The majority of tuberculous infections result from inhalation of airborne droplet nuclei 
carrying the causative bacteria (Ryan et al, 2010). Infection is established by interactions 
between M. tuberculosis and the host macrophages (Eley et al, 2009). The survival success of 
MTB, an intracellular pathogen, relies on avoiding the killing action of the host‟s phagocytes 
(Ryan et al, 2010).  
 
There are four distinct stages in pulmonary tuberculosis; inhalation of the tubercle bacilli,  
activation of blood monocytes and other inflammatory cells, cessation of early logarithmic 
bacillary growth , and dormancy of the infection.     
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1.11.1 Primary infection 
 
The initial encounter referred to as primary tuberculosis infection typically occurs in the 
macrophages (Eley et al, 2009). The inhaled pathogenic organism (stage one) deposited in the 
middle and lower lobes of the alveoli which are recognised by the alveolar macrophage 
complement receptors (CR1, CR3, CR4). The host‟s cell-mediated innate immune response is 
activated and the pathogen is phagocytosed (Ryan et al, 2010). Following phagocytosis by 
the macrophages, M. tuberculosis-specific adaptive cell mediated immunity develops (Eley et 
al, 2009).  
 
The destruction of mycobacteria is dependent on the host phagocytes‟ intrinsic microbicidal 
capacity and the ingested mycobacterial virulence factors. Immediate killing of the 
mycobacteria leads to no infection setting in, shown in Figure 1.2. Those mycobacteria that 
escape the initial intracellular killing (Smith, 2003) by interfering with the acidification of the 
phagosome and affecting lysosomal enzyme activity, making it less effective (Eley et al, 
2009), will multiply and be released from the macrophages. This process will attract blood 
monocytes and other inflammatory cells to the lung, referred to as stage two of pulmonary 
tuberculosis (van Crevel et al, 2002). We used to assume that tuberculosis results from a 
single infection with single M. tuberculosis strain. However there is evidence to suggest that 
mixed infections occur (Warren et al, 2004; van Rie et al, 2005; Cohen et al, 2011). 
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1.11.2 Reactivation 
 
In tuberculosis, organisms that are not killed during primary infection enter a dormant or 
stationary phase as a result of oxygen and nutrient deprivation.  Latent tuberculosis is present 
in one third of the world‟s population with less than 10% developing active disease (Eley et 
al, 2009; Bezuidenhout et al, 2009). Reactivation of the dormant infection occurs once the 
host experiences immunosuppression for a variety of reasons (Knechel, 2009) and may lead 
to the transmission of disease. M. tuberculosis reactivates at aerobic sites which favours 
growth of the aerobe MTB. Even though mycobacterial resuscitation-promoting factors have 
been identified, the mechanism of reactivation of these dormant foci is still poorly understood 
(Ryan et al, 2010). In developing countries with large immunosuppressed populations and/or 
settings of high TB incidence, the risk of re-exposure within the population is high and it is 
therefore difficult to determine whether recurrent TB disease can be attributed to reactivation 
or re-infection (Horsburgh, 2008). Charalambous et al have shown that HIV-infected gold 
miners are at higher risk of TB recurrence with a substantial portion resulting from re-
infection (Charalambous et al, 2008).  
 
In another report from a high tuberculosis incidence area in Cape Town, the age adjusted 
incidence rate of TB attributable to reinfection following successful treatment was four times 
that of new TB. These authors challenged the traditional belief that infection with one strain 
of TB in immunocompetent individuals protects against development of disease due to 
subsequent infection with a different strain. They suggest that patients who have been 
successfully treated for TB are at higher risk of developing disease from reinfection than the 
general population and that certain individuals are inherently vulnerable to TB disease 
(Verver et al, 2005). 
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Figure 1.2 Key pathogenic stages following MTB inhalation from droplet nuclei (Adapted 
from: van Crevel et al, 2002) 
 
1.12 Clinical Manifestations 
 
The clinical features of TB vary widely depending on the anatomical site or sites involved, as 
well as the bacillary population (Hopewell, 2008). The development of TB differs in each 
patient depending on the individual‟s immune system. The different stages are; latency, 
primary disease, primary progressive disease and extra-pulmonary disease. Different clinical 
features of each stage are described in figure 1.3 (Knechel, 2009).  
 
Immediate killing of 
MTB (no infection) 
 
Primary Complex 
(Infection) 
Localised disease 
(Primary TB) 
Dissemination of 
MTB 
Acute disease 
Containment (latency) 
Reactivation or re-infection 
Inhalation of M. tuberculosis 
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Cough is the universal indicator of tuberculosis with radiographs showing mid-lung 
infiltrates, and hilar lymphadenopathy in primary tuberculosis. The characteristic Ghon 
complex seen in radiographs are the result when lymph nodes fibrose and sometimes calcify 
(Ryan, 2010). In reactivated tuberculosis disease, radiography shows infiltrates in the apices 
of the lung coalesce to form cavities with progressive lung tissue destruction (Ryan, 2010). 
The clinical manifestations of tuberculosis are the same whether the patient is exposed in a 
high or low TB incident setting (Maher, 2009b). Growing evidence suggest that the genetic 
lineage of M. tuberculosis effects the clinical features of the disease (Malik et al, 2005). 
 
 
Figure 1.3 The different phases in tuberculosis disease progression (Adapted from; Knechel, 
2009). 
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1.12.1 Signs and symptoms 
 
The clinical signs and symptoms of TB are non-specific (Hopewell, 2008). Systemic 
symptoms, regardless of site of tuberculosis include fever, night sweats, tiredness, loss of 
appetite, weight loss, and secondary amenorrhoea (Maher, 2009b). 
 
1.12.2 Pulmonary tuberculosis 
 
Primary pulmonary TB maybe asymptomatic or it may present with clinical systemic 
symptoms (Ryan, 2010). The principle site of TB is the lungs with presenting clinical features 
of pulmonary TB being cough, sputum, chest pain, haemoptysis, and uncommonly 
breathlessness (Hopewell, 2008). Pulmonary TB patients co-infected with HIV experience 
weight loss and fever more than those patients who are HIV-negative. On the other hand, 
cough and haemoptysis are less common in HIV-positive patients. Unexplained productive 
coughing in patients for 2-3 weeks should be screened for TB since the sensitivity of cough 
as a predictor for TB is very high (Maher, 2009b).  
 
1.12.3 Extra-pulmonary tuberculosis 
 
The predominant location of tuberculosis is the pulmonary system but an increased risk of 
extra-pulmonary tuberculosis disease occurs in 20% of immunocompromised patients 
(Knechel, 2009). The high frequency of extra-pulmonary TB among HIV-infected population 
results from failure of the immune system to contain the infection, thereby assisting 
haematogenous spread and infection of one or multiple non-pulmonary sites (Hopewell, 
18 
 
2008). Patients with extra-pulmonary tuberculosis present with the same systemic features 
(Hopewell, 2008) with clinical signs and symptoms related to the pathology at the local site 
of disease (Maher, 2009b). 
 
The location of extra-pulmonary tuberculosis with the most severe disease is the central 
nervous system which results in meningitis or space occupying tuberculomas. Tubercular 
meningitis is fatal in most cases if untreated (Knechel, 2009). The acute dissemination of M. 
tuberculosis into the blood stream is referred to as miliary tuberculosis and the infection can 
spread throughout the body, leading to multi-organ involvement (Wang et al, 2007). Miliary 
TB progresses rapidly and can be fatal if not treated early. It is difficult to diagnose due to its 
systemic and nonspecific signs and symptoms (Knechel, 2009). Tuberculosis 
lymphadenopathy is the most common extra-pulmonary form of tuberculosis and most 
commonly presents with cervical lymph node enlargement (Maher, 2009b). Other sites for 
TB infections include the bone joints, pleura and genitourinary systems (Knechel, 2009). 
 
1.13 Diagnosis of tuberculosis 
 
Infectious TB disease with the high mortality rate worldwide spreads successfully due to the 
inability of health systems to detect sufficient number of cases prior to transmission to the 
uninfected population (Whitelaw et al, 2009). One of the key reasons for poor case detection 
is that TB is difficult to diagnose. Clinical and radiological findings provide only presumptive 
evidence in the diagnosis of TB (Somoskövi et al, 1999). The diagnosis of TB relies on the 
detection of TB bacteria in sputum, aspirates, biopsies or blood (Doherty, 2008). The bacteria 
can be detected by means of microscopy or culture but the sensitivity of these methods are 
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reliant on the quality of the specimen, concentration of bacteria and the volume of the 
specimen received (Whitelaw et al, 2009). In addition, MTB grows slowly resulting in longer 
turnaround times for culture, therefore the need for rapid new molecular diagnostic tests 
(Afanas‟ev et al, 2007). 
 
1.13.1 Specimen collection, storage and transport 
 
Microbiological diagnostic tests performances are dependent on the specimen quality which 
is required to be representative of the site of infection. Therefore specimens should be 
collected aseptically, and stored and transported to the laboratory with minimal delay (WHO, 
1998a) to prevent contaminating organisms from multiplying (Whitelaw et al, 2009).  
 
1.13.2 Smear microscopy 
 
Microscopic detection of M. tuberculosis is the most common method used worldwide 
because it is simple and inexpensive to perform (Doherty, 2008). Mycobacteria are difficult 
to stain with basic dyes (including those used in gram stain) because of the high lipid content 
of their cell wall. These acid-fast organisms resist decolorisation by acidified alcohol 
following prolonged application of a basic fuchsin dye. This property is referred to as acid-
fastness and is used in smear microscopy. The sensitivity of smear microscopy is reliant on 
the quality of the sputum collected (Urbanczik, 2010) and the underlying pulmonary 
pathology. There are currently two staining methods used: Ziehl-Neelsen (ZN) for light 
microscopy and Auramine-O fluorochrome staining for fluorescence microscopy shown in 
Figure 1.4 (WHO, 1998a). The Auramine method is preferred over ZN as it has an improved 
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sensitivity (by about 10%) and it is easily read, requiring less time to perform (Whitelaw et 
al, 2009). Overall microscopy only has 50-60% sensitivity (and even lower in HIV-positive 
population) hence a more effective method of diagnosing TB is required (Doherty, 2008). 
 
 
Figure 1.4 Microscopic images of M. tuberculosis (A- Ziehl-Neelsen B-Auramine-O)  
 
1.13.3 Culture 
 
Bacterial culture on solid or liquid media is the gold standard for diagnosis of M. 
tuberculosis. Cultures are also used to distinguish M. tuberculosis from other mycobacteria 
(Doherty, 2008) and to perform drug sensitivity testing (Wood, 2007). Prior to growing the 
bacteria on culture media, the specimen needs to be digested and decontaminated to remove 
other faster growing contaminating bacteria or fungi. The most commonly used 
decontamination and digestion methods are the sodium hydroxide (NaOH) method and the N-
acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) method (Whitelaw et al, 2009). During 
the decontamination process, some mycobacteria may be killed (WHO, 1998b). The 
bacterium in the specimen is concentrated by centrifugation to optimise yield. Once the 
A B 
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specimen is decontaminated, it is inoculated onto one or more culture media to achieve 
growth (See Figure 1.5).  
 
The different types of media used are (Whitelaw et al, 2009);  
Solid media used for culturing tubercle bacilli: 
 Lowenstein-Jensen (LJ) - an egg-based medum 
 Middlebrook 7H10 or 7H11 - agar-based medium, Dubos agar-based medium 
Liquid media used for culturing tubercle bacilli: 
 Middlebrook 7H9 broth 
 Dubos Tween albumin broth 
 
 
Figure 1.5 M .tuberculosis growing on solid (left) and liquid (right) culture media  
 
Although solid media are used widely due to the low cost, there are advantages in using 
liquid media for culturing TB (Doherty, 2008). One of the key advantages is the rapid growth 
of the bacteria in liquid media (8-12 days to give a positive growth), compared with solid 
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media (takes 6-8 weeks) (Wood, 2007). The isolation rates of the bacteria from liquid culture 
are higher especially when using the commercial liquid-based mycobacterial culture system 
such as Becton Dickson BACTEC MGIT 960 system (Whitelaw et al, 2009). The MGIT 960 
tubes contain 7ml of modified 7H9 both and the system is based on the consumption of 
oxygen by the growth of MTB which produces fluorescence when illuminated by a UV lamp, 
Fig.1.5 (Wood, 2007). The other two methods used for automated detection are the MB/BacT 
system which uses colorimetric CO2 detection and Trek ESP II system based on pressure 
changes in the headspace above the liquid culture in a sealed tube. The key disadvantage of 
the commercial liquid-culture systems is the high costs of the reagents and the equipment 
(Whitelaw et al, 2009) and higher contamination rates than with solid media.  
 
1.13.4 M. tuberculosis identification from culture 
 
Once growth is obtained on either solid or liquid media, microscopic examination (ZN 
staining) is performed to confirm the presence of acid fast bacilli and not contaminants 
(WHO, 1998b). Identification is the confirmed by one of several techniques:  
 
There are various techniques used to identify acid-fast bacilli from culture (Whitelaw et al, 
2009). 
1. Antigen detection: these lateral flow assays detect M. tuberculosis antigen specific to 
members of the MTB complex (examples include Capilia TB Rapid test that detects 
MPB64 antigen and SD Bioline Antigen Detection Test MPT 64). 
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2. Phenotypic methods determine the growth rates, pigmentation and growth at different 
temperatures of mycobacteria which differentiate them from NTM. Biochemical tests 
are also used but they are labour intensive, expensive, and results may be difficult to 
interpret. 
 
3. Genotypic methods are DNA- or RNA-based assays which rapidly identifies MTB 
with easy interpretation. A large number of nucleic-acid-based tests are available for 
the detection of MTBC; however, they do not differentiate between the different 
members of the complex. Specifically the Hain LPA has been endorsed by WHO for 
the rapid detection of MDR-TB (WHO, 2008). 
 
4. Mycolic acid analysis can be used to identify mycobacteria and is usually used to 
describe new mycobacterial species. High-performance liquid chromatography is used 
for these analyses in research settings only. 
 
1.13.5 Drug susceptibility testing  
 
The resistance to anti-tuberculosis drugs occurs naturally by the process of selection of drug-
resistant mutants by the treatment agent(s) (Whitelaw et al, 2009) resulting in some bacilli 
acquiring resistance to drugs used for treatment when they are poorly managed (Campbell et 
al, 2011). MDR-TB, is spreading worldwide requiring more complex and costly treatment 
regimens with worse outcomes (Whitelaw et al, 2009). The emergence of XDR-TB has 
highlighted the need for more DST as well as rapid diagnosis of the type of resistance 
(Campbell et al, 2011). 
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1.13.5.1 Phenotypic (conventional) drug susceptibility testing 
 
Phenotypic or conventional DST determines if the organism is resistant to an anti-
tuberculosis drug by evaluating growth of the organism in the presence of the drug (Whitelaw 
et al, 2009) compared with a control. There are different phenotypic methods employed in 
various laboratory settings including; absolute concentration or resistance ratio method, agar 
proportion method and MGIT 960 (Becton-Dickenson Diagnostics, Sparks, MD, USA) (van 
Deun et al, 2010). The down side to these methods is the time delay as solid media takes up 
to 4-6 weeks to completion and the liquid MGIT 960 system only gives a DST result 1-2 
weeks after the MGIT system flags positive for culture which itself takes 1-6 weeks (Al-
Mutairi et al, 2011). Mycobacteriophage-based methods, like the commercial 
FASTplaqueassay (Biotech labs Ltd, Iswich, UK) have been introduced incorporating DST 
which is based on the inhibition of replication of the bacteria in the presence of the drug 
giving a visual result within 2 days (van Deun et al, 2010).   
 
1.13.5.2 Genotypic (molecular) methods 
 
The molecular mechanisms conferring drug resistance have been described for several of the 
major first and second line anti-tuberculosis drugs. This understanding has facilitated the 
recent development of rapid molecular diagnostic tests for identification of drug resistance.   
Molecular methods or genotypic DST are DNA-based tests which identify mutations 
associated with drug resistance (Campbell et al, 2011). The major limitation to molecular 
methods is that for some anti-tuberculosis drugs not all resistance-conferring mutations have 
been well characterised for some anti-tuberculosis drugs (van Deun et al, 2010). Various in-
house molecular tests have been developed and used for the detection of resistance-
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determining mutations (Whitelaw et al, 2009). In 2008, the World health Organisation 
(WHO) endorsed the use of line probe assays (LPAs) for the rapid detection of MDR-TB 
(WHO, 2008). LPAs are based on multiplex polymerase chain reaction (PCR) amplification 
followed by reverse hybridisation for the identification of MTBC and the detection of 
resistance in the genes associated with the anti-tuberculosis drugs RIF and INH (Albert et al, 
2010). The commercial assay, INNO-LiPa (INNO-LiPa, Innogenetics, Ghent, Belgium) 
detects RIF resistance in the rpoB gene only (Al-Mutairi et al, 2011) while the MTBDRplus 
(Hain Lifescience, GmbH) LPA, detects mutations conferring resistance in the rpoB, katG 
and inhA genes and produces a result within 1 day (Barnard et al, 2007). More recently, in 
2010, WHO STAG-TB endorsed the use of the GeneXpert MTB/RIF (Cepheid, Sunnyvale, 
CA), a molecular test that detects Mycobacterium tuberculosis as well as rifampicin 
resistance. WHO recommended GeneXpert MTB/RIF as the initial diagnostic test for TB in 
individuals suspected of MDR-TB or TB/ HIV-co-infection (WHO, 2011b). 
  
DNA sequencing is considered the gold standard in which the nucleotide sequence of the 
amplified DNA is visible giving the most accurate result while DNA microarray (DNA 
biochip) assays have been developed for the detection of TB drug resistance but they have as 
yet not been fully evaluated.(van Deun et al, 2010).  
 
1.13.6 Genotyping methods used in TB Epidemiology 
 
Molecular methods are also used for epidemiological studies of MTB with many tools 
available, each with its own positive and negative characteristics (McEvoy et al, 2009). These 
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molecular tools have been used to give some insight into the genomic evolutionary changes at 
the DNA level (van der Spuy et al, 2008).   
 
1.13.6.1 IS6110 Restriction fragment length polymorphism (RFLP) 
 
The M. tuberculosis genome contains/includes many insertion sequences (IS) which are able 
to replicate and 'jump' or transpose themselves from one region to another thereby displaying 
polymorphism in the number of elements per genome (McEvoy et al, 2009). IS6110 is TB 
specific and is the most widely used genetic marker with IS6110 RFLP considered as the 
'gold standard' for MTB genotyping (Stavrum et al, 2009).    
 
1.13.6.2 Spoligotyping 
 
All MTBC members have the direct repeat (DR) chromosomal region which is composed of 
multiple 36-bp directly repeat sequences interspersed by non-repetitive unique spacer regions 
ranging from 35 to 41 bp in length (van der Spuy et al, 2008; McEvoy et al, 2009).One DR 
sequence and its spacer is referred to as direct variable repeat (DVR) where polymorphisms 
occur between MTB isolates (McEvoy et al, 2009). Spoliogotyping or spacer oligonucleotide 
typing is designed to determine the presence or absence of 43 spacer regions in 
M.tuberculosis isolates (van der Spuy et al, 2008). Spoligotyping has less discriminatory 
power to distinguish M. tuberculosis strains than IS6110 (RFLP) (Barnes et al, 2003).  
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1.13.6.3 MIRU/VNTR analysis 
 
This genotyping method is based on PCR amplification of mycobacterial interspersed 
repetitive units of variable-number tandem repeats (MIRU-VNTR) and has a higher 
discriminatory power than IS6110 RFLP (Stavrum et al, 2009). MIRU-VNTR can also be 
used to determine mixed subpopulations from the same sputum specimen (Allix et al, 2004).  
 
1.14 Treatment of Tuberculosis 
 
Many antimicrobials have been shown to be ineffective against mycobacteria due their 
unusually impermeable lipid-rich cell wall. There are a few groups of antimicrobials which 
are active and are used in the treatment of MTB (Ryan et al, 2010). The primary drugs of 
choice recommended by the WHO are referred to as the first-line anti-tuberculosis drugs 
which are administered as a 6-month short course. Pyrazinamide and ethambutol together 
with INH and RIF are given for the first 2 months during the intensive phase of treatment 
followed by INH and RIF for the next 4 months (WHO, 2009). The injectable streptomycin 
may also be used in the initial phase of treatment but its usefulness has decreased over time 
due to increasing resistance to the drug (Donald et al, 2009).  Second-line drugs are reserved 
for use when there is resistance to first-line drugs, drug intolerance or toxicity (WHO, 2009).  
 
1.15 Molecular Basis and Mechanisms of Resistance to First-line Drugs 
 
Resistance of M. tuberculosis to anti-tuberculous drugs results from a spontaneous genetic 
event, occurring at a frequency of 10
-5
 to 10
-8
. Resistance to various drugs arises 
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independently (Pfyffer, 2000). Resistance in M. tuberculosis appears to be confined to 
chromosomal DNA and does not involve transfer of mobile genetic elements (such as 
plasmids) which occurs in other bacteria and mycobacteria (Pfyffer, 2000). 
 
Resistance to the first-line anti-TB drugs occurs through sequential accumulation of 
mutations in the genes targeted by the drugs (Johnson et al, 2007).  These mutations occur at 
the drug target region or at the enzymes that are involved in the activation of the drug 
(Somoskovi et al, 2001). These drug-resistant strains develop when chemotherapy is 
disrupted or otherwise inadequate (Ramaswamy et al, 1998).  
 
The molecular mechanisms conferring drug resistance have been described for several of the 
major first and second line anti-tuberculosis drugs. This understanding has facilitated the 
recent development of rapid molecular diagnostic tests for identification of drug resistance 
(Zhang et al, 2009). While about 96% of rifampicin resistant isolates have mutations in a 
defined region of the rpoB gene, resistance to isoniazid is more complicated, involving at 
least two gene katG and inhA which together account for approximately 65-75% of resistant 
strains (Ramaswamy et al, 1998). For other drugs, known drug resistance mutations occur in 
a smaller proportion of isolates suggesting other mechanisms of resistance. Genes commonly 
associated with resistance to anti-tuberculous drugs are summarised in Table 1.1 below 
(Zhang et al, 2009; Ramaswamy et al, 1998). Several studies have shown that the frequency 
distribution of mutations among drug resistant isolates shows geographic variability both 
between and within countries (Barnard et al, 2008; Ohno et al, 1996; Miotto et al, 2006; 
Green et al, 2008).  
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Table 1.1 Summary of genes commonly associated with resistance to anti-tuberculosis drugs 
 
Drug Gene(s) involved in 
resistance 
Mutation frequency 
% 
Isonaizid katG, 
 inhA 
50-95 
8- 43 
Rifampicin rpoB 95 
Pyrazinamide pncA 72-97 
Ethambutol embB 47-65 
Streptomycin rpsL,  
rrs,  
gidB 
52-59 
8-21 
Unknown 
Amikacin/kanamycin rrs 76 
Capreomycin tlyA Unknown 
Quinolones gyrA, gyrB 75-94 
Ethionamide etaA/athA,  
inhA 
37 
56 
PAS thyA 36 
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1.15.1 Isoniazid 
 
INH is a pro-drug with a simple structure containing a pyridine ring and a hydrazide group 
requiring activation (Somoskovi et al, 2001; da Silva et al, 2011). Almost all mycobacteria 
and prokaryotes other than M. tuberculosis are resistant to INH (Ramaswamy et al, 1998).  
INH is activated by the catalase/peroxidase enzyme encoded by katG which prevents the 
synthesis of mycobacterial mycolic acids by inhibiting the NADH-dependent enoyl-ACP 
reductase coded by inhA (da Silva et al, 2011). The basis of resistance to INH is more 
complex and is based on a genetic system involving a large number of gene regions such as 
katG, inhA, kasA, aphC, oxyR and less common iniA, iniB and iniC genes (Afanas'ev et al, 
2007; Wei-Wei et al, 2007). Studies have shown that katG covers a wide range of 50-95% of 
INH resistance in isolates while inhA resistance is present in 20-35% of isolates (Wei-Wei et 
al, 2007; Aslan et al, 2008).  
 
Molecular genetic studies have correlated INH resistance with loss of catalase-peroxidase 
activity which is controlled by the katG gene (Ramaswamy et al, 1998). Mutations in the 
catalase-peroxidase gene, usually at codon 315, prevent the conversion of the INH pro-drug 
into its active form (Wei-Wei et al, 2007). The promoter region of the inhA operon comprises 
two genes, fabG1 (mabA) and inhA (Afanas'ev et al, 2007; Ramaswamy et al, 1998). The 
metabolic activity of the operon is to code for β-ketoacyl reductase and the fatty-acid enoyl-
acyl carrier protein reductase which participate in mycolic acid biosynthesis (Afanas'ev et al, 
2007). Missense mutations in the promoter region (position -15T or -8C) result in over 
expression of the target for the active INH radical leading to INH resistance (Afanas'ev et al, 
2007; Evans et al, 2009). Mutations in the katG gene code predominantly for high-level 
resistance to INH while low-level resistance is determined mainly by mutations present in the 
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inhA gene (Barnard et al, 2008; van Deun et al, 2010). Resistance to the anti-tuberculosis 
drug ethionamide is also cause by mutations in the inhA gene. Further research is required to 
better understand the mechanisms responsible for INH resistance in the other genes 
(Afanas'ev et al, 2007).  
 
1.15.2 Rifampicin 
 
RIF is a lipophylic ansamycin with efficient antimicrobial activity and is considered a key 
drug in the treatment of tuberculosis (da Silva et al, 2011). The activity of RIF involves 
binding to the β-subunit of ribonucleic (RNA) polymerase resulting in inhibition of 
transcription (Wei-Wei et al, 2007). Resistance to RIF is caused by amino acid substitutions 
as a result of missense mutations, or deletions or insertions in this region encoding the β-
subunit of the RNA polymerase enzyme (Aslan et al, 2008; Ramaswamy et al, 1998). 
Resistance to RIF is largely confined to mutations present in an 81 base pair hotspot region 
on the rpoB gene (Aslan et al, 2008; Ramaswamy et al, 1998). This drug resistance region is 
known as the RIF resistance-determining region (RRDR) (Afanas'ev et al, 2007; Evans et al, 
2009; WHO, 2007). The RRDR spans from codon 507 to 533 of the rpoB gene and more than 
95% of resistant strains harbour mutations in this region (Afanas'ev et al, 2007; Evans et al, 
2009; Wei-Wei et al, 2007).  
 
The characterisation of the M. tuberculosis rpoB gene showed a wide variety of distinct 
alterations in the RRDR in epidemiologically unrelated patient isolates (Ramaswamy et al, 
1998). Studies have commonly documented missense mutations at codon 531 (Ser), 526 (His) 
resulting in amino acid replacements. Amino acid substitutions Ser513Leu and His526Tyr 
32 
 
were most common (Afanas'ev et al, 2007). Several research groups have investigated the 
relationship between RIF MIC levels and structural changes found in the rpoB gene 
(Ramaswamy et al, 1998). They had found a strong correlation between rpoB variants and 
RIF MICs. High-level drug resistance to rifampicin, rifabutin and rifapentine had amino acid 
substitutions at codons 513, 526 and 531, whereas, amino acid substitution at positions 514, 
521 or 533 conferred low-level resistance to RIF. In RIF resistant isolates that lacked changes 
in the RRDR, the molecular mechanisms involved are unknown (Ramaswamy et al, 1998). 
 
1.15.3 Streptomycin 
 
Streptomycin (STR) is aminocyclitol glycoside antibiotic and was the first antibiotic used in 
TB treatment (da Silva et al, 2011). STR resistance is associated with the 16s rRNA gene, rrs 
and rpsL which encodes for the ribosomal protein S12 (Ramaswamy et al, 1998). 
 
1.15.4 Ethambutol 
 
Ethambutol (EMB) ([S,S']-2,2'-[ethylenediimino])di-1-butanol has bactericidal activity and 
was first used against TB in 1966 (da Silva et al, 2011). It interferes with the biosynthesis of 
the cell wall arabinogalactan. Mutations in the embB operon are responsible for EMB 
resistance (Ramaswamy et al, 1998). 
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1.15.5 Pyrazinamide  
 
Pyrazinamide (PZA) is a pro-drug introduced in the TB treatment regimen in the 1950s with 
the ability to inhibit semi-dormant bacilli (da Silva et al, 2011). PZA is an analogue of 
nicotinamide and in its active form, pyrazinoic acid encoded by the mycobacterial enzyme 
pyrazinamidase (PZase), prevents fatty acid synthesis (Somoskovi et al, 2001). Mutations in 
the pncA gene which codes for the PZase enzyme is the main target for resistance (da Silva et 
al, 2011). 
 
1.16 Immunity and TB vaccines 
 
Each year millions of infants are vaccinated with the BCG (BacilleCalmette-Guerin) vaccine 
to prevent severe disease such as meningitis and miliary TB (Dye et al, 2008). BCG is safe 
and may elicit long-term protective immunity but the escalating TB epidemic worldwide has 
occurred even with the widespread use of BCG vaccines. The global increase of TB related 
mortality shows that the BCG vaccine has failed and the development for new more effective 
vaccines is required (Hussey et al, 2009). 
 
1.17 Experimental proposal 
 
1.17.1 Study Background Problem 
 
The HIV epidemic and emergence of drug-resistant TB threaten global control of TB.  MDR-
TB has escalated worldwide due to inadequate detection, diagnostic delays and low TB cure 
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rates (Barnard et al, 2008). The conventional methods of drug susceptibility testing (DST) 
require a minimum of 14 days for completion as these phenotypic methods are still dependent 
on the growth of the M. tuberculosis bacteria in culture (Afanas‟ev et al, 2007). The growing 
burden of drug resistance together with outbreaks of XDR-TB prompted international calls 
for new rapid molecular diagnostics tools for early diagnosis of drug resistant TB (WHO, 
2008). Improved understanding of the molecular mechanisms conferring TB drug resistance 
facilitated the recent development of such tests. 
 
SA is a low to middle income country with a high incidence of TB including large numbers 
of drug resistant TB and high rates of HIV co-infection. A severe outbreak of XDR-TB in 
KwaZulu-Natal, where 52 out of 53 patients died within two weeks of diagnosis (Gandhi et 
al, 2006) highlighted the public health crisis. In 2007 South Africa participated in a large-
scale demonstration project funded by the Foundation for Innovative New Diagnostics 
(FIND) to assess implementation and benefits of the use of new molecular diagnostic tests for 
the rapid detection of MDR-TB (WHO, 2008).  Improved case finding and early 
implementation of appropriate treatment could reduce transmission, improve individual 
outcomes and prevent progression to XDR-TB. 
 
The GenoType MTBDRplus (Hain Lifescience, GmbH) line probe assay (LPA) is a 
molecular diagnostic test based on the polymerase chain reaction (PCR) and reverse 
hybridization and is designed to detect M. tuberculosis and drug resistance to INH and RIF 
(Evans et al, 2009). The probes present on the LPA are specific for the detection of mutations 
present in the rpoB, katG and the promoter region of the inhA genes (Barnard et al, 2008; 
Matsoso et al, 2010). The distribution of mutations resulting in drug resistance in M. 
tuberculosis varies geographically, from region to region (Aslan et al, 2008; Evans et al, 
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2009). This highlights a limitation of the use of genotypic LPA in that it only covers the most 
frequent mutations conferring resistance (Bolotin et al, 2009) to the anti-tuberculosis drugs. 
Resistance due to mutations not represented in the molecular assay will result in 
discrepancies between genotypic composition on LPA and phenotypic expression of 
resistance with genotypic resistance in a strain being falsely labelled susceptible by the LPA. 
Also, silent mutations detected by the LPA will be associated with phenotypic susceptibility. 
 
The wide use of genotypic assays for the detection of drug resistance would require constant 
monitoring of local drug resistance mutations within a country to prevent emergent clonal 
groups of M. tuberculosis from not being appropriately detected and classified (Evans et al, 
2009). The high rate of HIV co-infection within the population of SA has contributed to the 
large M. tuberculosis pool from which new mutations in genes concerned with the action of 
anti-TB drugs can be selected, potentially resulting in cases where the LPA fails to detect 
resistance to the drugs.  
 
Globally the TB epidemic consists of multiple genotype-specific sub-epidemics and over 
time the most „successful‟ genotypes become dominant in different geographical locations. In 
developed and developing countries like SA, the bacterial population structure of resistant 
isolates is not well documented. The genotype profiles for the MDR-TB population causing 
disease across the country are largely unknown.  
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1.17.2 Study Objectives 
 
1.17.2.1 Hypothesis 
 
In SA, there is regional variation in the mutations encoding INH and RIF resistance in M. 
tuberculosis isolates. Some of these mutations are not represented on probes used in the LPA 
for the detection of MDR-TB. This results in discrepancies between genotypic and 
phenotypic resistance.  
 
1.17.2.2 Aim 
 
To determine the frequency, distribution and genetic basis of LPA/MGIT DST discordant 
findings in four provinces of South Africa that participated in a demonstration project to 
assess the effectiveness of a rapid line probe assay for presumptive MDR-TB diagnosis in 
smear-positive specimens from patients in high TB burden countries.  
 
1.17.2.3 Specific objectives 
 
1. To determine the frequency and distribution of genotypic/phenotypic 
discrepancies in four provinces in South Africa. 
2. To repeat the LPA and phenotypic testing of all discordant samples included in 
study.  
37 
 
3. To determine Minimum Inhibitory Concentrations (MIC) of RIF and INH on 
isolates demonstrating phenotypic-genotypic discrepancies in resistance to these 
agents. 
4. To use the LPA as a screening tool on all discrepant samples to determine the 
genes involved in resistance.  
5. To perform sequencing on a selective basis to determine mutations that may be 
important for LPA testing based on objectives 1, 2, 3 and 4. 
6. To characterize the isolates by spoligotyping to determine geographical 
distribution of multidrug-resistant M. tuberculosis families. 
 
1.17.3 Study Outcomes 
 
Selective sequencing of relevant genes in M. tuberculosis isolates showing discordant 
genotypic/phenotypic resistance results may help identify novel mechanisms of resistance. 
The results from MICs will assist in evaluating the need and role of these anti-tuberculosis 
drugs in the current TB control program in SA. From further genotype investigations, we 
would like to address the geographical distribution of M. tuberculosis genotypes from one 
province to another as well as to gain a better understanding of the molecular epidemic and 
genetics involved in drug resistance. 
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Chapter 2 
 
2 Materials and Methods 
 
2.1 Source of isolates for the present study 
 
In 2007, four provinces in South Africa participated in a country-wide demonstration project  
in which smear microscopy-positive patients at high risk of drug-resistant-TB were enrolled 
to assess the use of the GenoType® MTBDRplus (Hain Lifescience GmbH, Nehren, 
Germany) line probe assay  (Hain LPA) for the diagnosis of MDR-TB under routine National 
Tuberculosis Control Program (NTBCP) conditions. (ML van der Walt, G Coetzee, M 
Sewpersadh, M Barnard, L Matsotso, R O‟Brien, R Odendaal, H Albert, publication in 
preparation). 
 
During this demonstration study a number of M. tuberculosis isolates were identified that 
showed discordant drug susceptibility results when tested with the Hain LPA and 
conventional phenotypic DST.  These isolates from Western Cape, KwaZulu-Natal, Gauteng 
and Northern Cape were included in the present study. Discordant results were defined as, 
differences between genotypic findings by the Hain LPA and conventional DST results for 
the anti-tuberculosis drugs RIF and INH. Based on this definition, cultures from 171 
genotypic/phenotypic discordant results from the demonstration study were available for 
further study.  
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2.2 Laboratory methods for characterization of discordant cultures 
 
All available isolates identified as discordant in the original demonstration study were re-
tested using Hain LPA and broth-based phenotypic DST for INH and RIF. Isolates confirmed 
to have discordant results on this repeat testing were further characterised by determination of 
minimum inhibitory concentrations (MIC) and by spoligotyping. Finally, sequencing of RIF 
and INH resistance-related gene regions was performed when phenotypic resistance was 
reported but no genetic changes were identified on the LPA.  
 
2.2.1 Phenotypic drug susceptibility testing 
 
The original MGIT culture specimens from Gauteng and KwaZulu-Natal were collected from 
the NHLS laboratories while aliquots of the MGIT culture from the Cape Town NHLS 
laboratory were transferred into 2 ml screw-capped tubes and transported to MRC. All these 
cultures were stored in the MRC Biosaftey Level 3 Laboratory (BSL 3) at room temperature. 
Prior to this study, the Northern Cape MGIT cultures were collected and stored at -20ºC at 
the Sandringham NHLS Laboratory.  Following retrieval, the frozen stock of the culture was 
left to thaw at room temperature and then 1 ml was inoculated into a MGIT 960 tube and 
incubated in the MGIT 960 machine until positive growth was attained. The sub cultures 
were then sent to MRC and stored with the rest of the culture collection.  
 
The specimens were cultured using the MGIT 960 method (Becton Dickinson Microbiology 
Systems, Cockeysville, MD, USA) according to the manufacturer‟s instructions. MGIT tubes 
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were incubated until a positive growth signal on the MGIT 960 machine was obtained (day 
0). The purity of the culture was tested by streaking the culture onto blood agar plates which 
were then incubated for 48 hours at 37°C for the detection of rapidly growing contaminants.  
If no growth appeared on the plates, drug susceptibility tests were set up. Prior to setting up 
the DST‟s the Hain LPA was done on the positive cultures to confirm the presence of M 
.tuberculosis. The MGIT tubes were incubated at 37°C and on day 2, DST to first-line drugs, 
RIF and INH, was performed on pure cultures using critical concentrations of 1.0 µg/ml for 
RIF and 0.1µg/ml for INH.  Three MGIT 960 tubes were labelled and used for each test 
culture (one for RIF, one for INH and one for the growth control).  
 
Aseptically 0.8 ml of BACTEC 960 SIRE supplement (Becton Dickinson Microbiology 
Systems, Cockeysville, MD, USA) was added to each of the tubes. 100 µl of the reconstituted 
drug was added to the corresponding drug labelled MGIT tubes but no drug was added to the 
growth control tube. 500 µl of the well-mixed culture suspension was added into the MGIT 
tubes containing the drugs. In the growth control tube, the culture suspension was diluted to 
1: 100 (100 µl of the culture added to 10 ml of sterile saline) and 500 µl of the diluted 
suspension was added to the growth control tube. All tubes were mixed well by gently 
inverting each tube a few times, after which they were placed into the MGIT machine set 
carrier in the correct drug sequence for incubation. The instrument generated the results 
within 5 to 13 days.  
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2.2.2 Genotypic drug susceptibility testing 
 
Hain LPA was performed in three separate rooms, according to WHO recommendations 
(WHO, 2008). DNA extraction was performed in a BSL3 cabinet, the master mix preparation 
was performed in the second room and the amplification by PCR and hybridisation for 
amplicon identification were performed in the third laboratory. One thousand microlitres of 
liquid culture was used to perform the GenoType® MTBDRplus assay according to 
manufacturer‟s instructions (Hain Lifescience, GenoType MTBDRplus user‟s manual).  
 
DNA extraction was performed by centrifuging the liquid culture for 5 minutes at 10 000 X 
g, then discarding the supernatant and re-suspending the pellet in 100 µl of sterile distilled 
water. The bacterial suspension was boiled at 95°C for 20 minutes and the cells were 
disrupted in an ultra-sonic water bath for 15 minutes. The mixture was centrifuged at 13 000 
X g for 5 minutes, then 50 µl of the supernatant was placed into a clean tube and  used as the 
template DNA for amplification. 
 
Each PCR mixture contained 35 µl  of PNM mix supplied by manufacturer (Hain Lifescience 
GmbH), 5 µl of 10x buffer (Qiagen, Benelux B.V), 2 µl 25 mM MgCl2 (Qiagen, Benelux 
B.V), 0.2 µl (1 unit) HotStarTaq (Qiagen, Benelux B.V), 3 µl molecular grade water (Qiagen, 
Benelux B.V), and 5 µl template DNA. The mixture was subjected to the following cycling 
conditions; 1 cycle at 95°C for 15 minutes (min), 10 cycles each of, 95°C for 30 seconds 
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(sec), 58°C for 2 min, 20 cycles each of 95°C for 25 sec, 53°C for 40 sec, 70°C for 40 sec 
and 1 cycle at 70°C for 8 min. 
 
Reverse hybridisation was performed on the automated GT Blot system (Hain Lifescience 
GmbH) and the LPA strips were read manually.  
 
2.2.3 Determination of the minimal inhibitory concentrations (MICs) 
 
MICs were determined using the Alamar Blue assay as previously described (Franzblau et al, 
1998).  
 
2.2.3.1 Preparation of inoculum stock 
 
The optical density (OD) readings of each bacterial culture were measured using a 
spectrophotometer (Beckman, CA) at a wavelength of 600 nanometres (nm). The bacterial 
suspension was then diluted in 7H9 medium (Sigma Chemical Co, St Louis, Mo) containing 
15% glycerol and OADC supplement (Becton Dickinson Microbiology System, 
Cockeysville, MD, USA) to obtain a bacterial inoculum of ~1 X 10
5
- 1 X 10
7
colony-forming 
units (cfu) /ml.  
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2.2.3.2 Preparation of drugs 
 
RIF and INH (Sigma Chemical Co, St Louis, Mo) drugs were freshly prepared on the day of 
the experiments.  INH antibiotic powder was dissolved in sterile distilled water and RIF 
powder was dissolved in 100% dimethyl sulfoxide (DMSO) to a final concentration of 10 
mg/ml. A 1:2 serial dilution of each drug was made in a 96-well plate. 2 µl of each drug 
dilution was transferred to its appropriate well in the assay plates. 
 
2.2.3.3 Alamar Blue assay  
 
In the sterile 96 well plate (Cellstar, Greiner Bio-one, GmbH), 200 µl of sterile distilled water 
was added to the outer-perimeter wells to minimise evaporation in the test wells during 
incubation. To the remaining wells (wells in rows B-E and in columns 2-10), 98 µl of 7H9 
medium (Sigma, Chemical Co, St Louis, Mo) containing 15% glycerol and OADC 
supplement (Becton Dickinson Microbiology Systems, Cockeysville, MD, USA) were added. 
Serial dilutions of RIF (in DMSO) and INH (in deionised water) with final drug 
concentrations ranging from 0.03 µg/ml to10 µg/ml for each of INH and RIF, were prepared. 
2 µl of the drug dilutions were added in columns 2-10, and column 11 was drug free as it 
served as a  control (100 µl of 7H9 was added in the control column 11). 100 µl of the culture 
inoculum (~1 X 10
5
-1 X 10
7
 cfu/ml) were added to columns 2-11. The plate was incubated at 
37°C for 6 days. After incubation 50 µl of 1:1 mixture of 10X Alamar blue reagent 
(Separations, Johannesburg, South Africa) and 10% Tween 80 (Sigma, Chemical Co, St 
Louis, Mo) to column 11 (drug free – inoculums only). The plate was re-incubated at 37°C in 
for 24 hours. If column 11 turned pink (indicating growth) the reagent mixture was added to 
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all wells in the microplate. If the control remained blue, the reagent mixture was added to 
another control well and was read on the following day. The microplates were incubated for 
24 hours at 37°C, and the colours were recorded. A blue colour in the well was interpreted as 
no growth and a pink colour was an indication of growth. The MIC was defined at the lowest 
drug concentration which prevented growth i.e. prevented a colour change from blue to pink.  
 
2.2.4 Spoligotyping 
 
Spacer oligonucleotide genotyping (spoligotyping) was used to confirm the species and 
determine the genotype of M. tuberculosis complex cultures included in the study 
(Kamerbeek et al, 1997). 
 
2.2.4.1 Amplification of spacer DNA by PCR 
 
Amplification of spacers was accomplished by using the primes DRa and DRb, which enable 
to amplify the whole DR region. PCR products are labelled with biotin, because primer DRa 
is biotinylated. The genotype determination was done using a spoligotyping kit (Ocimum 
Biosolutions, Hyderabad, India) and was used as per manufacturer‟s instructions (Ocimum 
Biosolutions, spoligotyping kit user manual). The method included two positive controls, M. 
tuberculosis H37Rv and M. bovis BCG and molecular grade water was used as the negative 
control. Each 40 µl amplification mixture contained 2 µl template DNA, 3 µl primer DRa 
(0.2 µmol/µl) 3 µl primer DRb (0.2 µmol/µl), 20 µl 2xTaq MasterMix (Qiagen, Benelux 
B.V), and 12 µl molecular grade water (Qiagen, Benelux B.V). Amplification was performed 
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at the following temperature cycling conditions; 1 cycle of each, 3 min at 94°C, 1 min at 
94°C, 1 min at 55°C, 25 cycles for 30 sec at 72°C, 1 cycle for 7 min at 72°C, and hold cycle 
at 4°C. 
 
2.2.4.2 Hybridization of PCR product and detection 
 
The hybridization of the biotin-labelled PCR products to the immobilized 43 spacer-
oligonucleotides that represent spacers of known sequence was performed as per 
manufacturer‟s instructions (Ocimum Biosolutions, Hyderabad, India). The presence of 
spacers were visualised on film as black squares after incubation with streptavidin-
peroxidase, conjugate, washing and rinsing, followed by  detection of hybridizing DNA using  
chemiluminescent ECL-detection liquid (Amersham Biosciences, UK), and finally exposure 
to X-ray film (Hyperfilm ECL, Amersham Biosciences, UK). 
 
2.2.5 Sequencing technology 
 
Using PCR and sequencing technology, previously described (Campbell et al, 2011) genes 
associated with the mechanisms of action of, resistance to RIF and INH, (rpoB, katG and 
inhA), were targeted to determine the genetic basis of resistance in isolates where no genetic 
alteration was detected by the Hain LPA.  
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2.2.5.1 DNA preparation for sequencing 
 
The crude DNA extract used for the Hain LPA was cleaned up using the QIAquick PCR 
purification kit (Qiagen, Benelux B.V) as per manufacturer‟s instructions. We had used 10 µl 
of template DNA and reduced the volumes accordingly for all other regents used in the kit.  
 
2.2.5.2 Amplification of gene regions 
 
The drug resistance-determining regions of rpoB, the promoters of inhA and regions with 
established resistance associated mutations of katG loci were amplified using locus-specific 
primers (see Table 2.1). Each 25 µl PCR mixture contained 12.5 µl HotStarTaq master mix 
(Qiagen, Benelux B.V), 1.5 µl of the forward and reverse 5 µM primers, 8.5 µl distilled H2O, 
and 1 µl of genomic DNA. The amplification parameters included an initial denaturation step 
at 95°C for 15 min, followed by 35 cycles of denaturation at 95°C for 30 sec, annealing at 
60°C for 30 sec, and elongation at 72°C for 30 sec, with a final elongation step at 72°C for 7 
min. All primers were synthesised by Inqaba Biotechnical Industries, Pretoria, South Africa. 
PCR products were analysed on 1.5% agarose –Tris-EDTA (Sigma, Chemical Co, St Louis, 
Mo) gels and stained with ethidium bromide (Sigma, Chemical Co, St Louis, Mo). Verified 
PCR products were cleaned using the QIAquick PCR purification kit (Qiagen, Benelux B.V) 
and were used as template DNA for sequencing. 
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Table 2.1 PCR and Sequencing Primers (Campbell et al, 2011) 
Locus Primer Sequence (5'-3') 
Size 
(bp) 
F or R Accession # Position 
Product 
(bp) 
Note 
rpoB rpoB-1f 
CTTGCACGAGG
GTCAGACCA 
20 F NC000962 1023-1042 543 RRDR
* 
 rpoB-2r 
ATCTCGTCGCTA
ACCACGCC 
20 R NC000962 1546-1565 543 RRDR 
inhA inhA-1f 
TGCCCAGAAAG
GGATCCGTCATG 
23 F NC000962 (-162)-(-140) 455 promoter 
 inhA-2r 
ATGAGGAATGC
GTCCGCGGA 
20 R NC000962 436-455 455 promoter 
katG katG-1f 
AACGACGTCGA
AACAGCGGC 
20 F NC000962 1433-1452 455 
codon 
315 
 katG-2r 
GCGAACTCGTCG
GCCAATTC 
20 R NC000962 998-1017 455 
codon 
315 
*
RRDR- rifampicin resistance-determining region 
 
Sequencing reactions (20 µl reaction mixtures) were completed with an ABI BigDye 
Terminator (version 3.1) cycle sequencing kit and the reactions included 4 µl of BigDye 
Terminator (version 3.1) reagent (ABI), 2 µl of 1.6 µM primer (with the same sequences used 
for PCR), 2 µl of 5X reaction buffer (ABI), 11 µl of distilled H2O, and 1 µl of PCR template. 
PCR products were sequenced with a forward and a reverse primer at each locus for 
maximum coverage and reproducibility of results. The reactions were cycled according to 
manufacturer‟s guidelines. The unincorporated terminators were removed from the completed 
reactions by treatment with BigDye Xterminator kit (ABI), using the manufacturer‟s protocol 
and were examined using 3130xl genetic analyzer with standard run conditions for 
electrophoresis and data collection. 
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2.3 Data Analysis 
 
2.3.1 Statistical analysis 
 
Descriptive statistical analysis was applied initially to calculate the frequency and identify the 
proportion of discordant findings in each province using the statistical software, STATA 10. 
Comparative analysis was done on the genotypic and phenotypic results as well as on the 
MICs using Microsoft Excel 2007. 
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Chapter 3 
 
3 Results 
 
3.1 Study group 
 
During the period June 2007- August 2008, 30 800 TB suspects at high risk for drug 
resistant-TB were screened in a large-scale demonstration project assessing the 
implementation and benefits of a new molecular diagnostic test for the rapid detection of 
MDR-TB under National Tuberculosis Control Programme (NTCP) conditions. The 
demonstration project‟s database was reviewed using statistical analysis (STATA 10) to 
identify specimens originally classified as discordant in the project for use in this study. 
Discordant was defined as differences between genotypic findings by the Hain LPA and 
conventional DST results for the anti-tuberculosis drugs RIF and INH. A total of 171 
discordant cultures were identified and collected from the provinces after completion of the 
demonstration project. Overall only 69.0% (118/171) of the stored culture isolates yielded 
pure isolates when sub-cultured in MGIT instruments and or on solid media as shown in 
Figure 3.1. 
 
Initially 44 cultures were contaminated and were re-decontaminated using 4% sodium 
hydroxide (NaOH). Following re-decontamination, (Figure 3.1), 37 /44 failed to grow in 
MGIT 960 as well as in 7H9 medium. Seven samples grew in 7H9 media, which were 
transferred into MGIT 960 tubes and were included with the „clean‟ group once positive 
growth was obtained and their identification was confirmed by Hain LPA for entry into the 
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study. The LJ cultures of the 37 samples gave poor growth, contamination or no growth and 
therefore had to be excluded. A further 16 samples were excluded from the positive growth 
group as they showed persistent contamination during DST and no results were available for 
RIF and INH. DST‟s were repeated three times on these samples prior to exclusion from the 
study.  
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Figure 3.1 Flow diagram showing INH and RIF genotypic/phenotypic discordant study group 
selection. 
 
171 discordant 
cultures  
44 contaminated 
(Subbed in MGIT) 
37 failed to grow 
Re-decontaminated 
Put in 7H9 + LJ+ 
MGIT  
Culture failed to grow 
without 
contamination-
excluded from study 
7 positives 
134  Positive cultures 
(127 + 7) - DST done 
134 LPA  Results  
134 DST done 
41 Discordant 
"Study group" 
118 DST Results 
16 cultures  
persistanly 
contaminated-
exculded from study 
127 'clean' 
cultures 
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3.1.1 The frequency and distribution of INH and RIF genotypic/phenotypic discordant 
isolates. 
 
The samples were distributed across four of the nine provinces in SA; Western Cape, 
Northern Cape, KwaZulu-Natal and Gauteng. The distribution of the phenotypically and 
genotypically discordant samples for both the demonstration project and this study are shown 
in Table 3.1. In the original demonstration project, Gauteng had the lowest percentage of 
discordant samples at 2.6% (20/763) and the Western Cape the highest percentage, 9.2% 
(117/1266). Northern Cape and KwaZulu-Natal provinces had 4.7% (11/233) and 3.4% 
(23/666) discordant samples province respectively.  
 
A large proportion of discordant samples were from Western Cape (68.4%), with KwaZulu-
Natal and Gauteng contributing 13.5% and 11.7% respectively. Only 6.4% of the samples 
were from Northern Cape.  Of the original 171 discordant samples, 118 were suitable for re-
testing with Hain LPA and conventional DST, 77 gave concordant results for 65.3% (77/118) 
of samples which were previously recorded as discordant. These were excluded from the final 
study group. 
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Table 3.1 Distribution of INH and RIF genotypic/phenotypic discordant M. tuberculosis 
samples in the 4 provinces 
 
Province 
Demonstration Project Excluded Study 
No of 
Specimens 
Enrolled 
No of 
Discordant 
Samples 
% of 
Study 
samples 
No 
Growth 
Not 
Discordant 
Study 
Group 
% 
Western 
Cape 
1266 117(9.2%) 
68.4 
(117/171) 
14 69 34 
82.9 
(34/41) 
Northern 
Cape 
233 11(4.7%) 
6.4 
(11/171) 
2 5 4 
9.8 
(4/41) 
KwaZulu-
Natal 
666 23(3.4%) 
13.5 
(23/171) 
21 1 1 
2.4 
(1/41) 
Gauteng 763 20(2.6%) 
11.7 
(20/171) 
16 2 2 
4.9 
(2/41) 
Total 2928 171(5.8%) 100.0 53 77 41 100.0 
 
The final distribution of the study group samples for each province is shown in Figure 3.2. 
The majority of the samples in this study were from Western Cape, 82.9% (117/171). 
Gauteng had the lowest number of discordant samples, contributing 2.6% (20/763) and the 
Western Cape with the highest number of discordants, 9.2% (117/1266). Northern Cape and 
KwaZulu-Natal provinces were represented by 4.7% (11/233) and 3.4% (23/666) of the 
samples for each province respectively.  
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Figure 3.2 Provincial distribution of the INH and RIF discordant study group (SG) samples 
 
3.1.2 Repeat LPA and phenotypic testing of all discordant isolates found in the 
demonstration project. 
 
The conventional MGIT (phenotypic) DST for RIF and INH as well as the Hain LPAs 
(genotypic) were performed on the 118 cultures with 34.8% (41/118) of specimens 
confirming INH and/or RIF discordant results and entered into this study. The Hain LPA was 
interpreted in accordance with manufacturer‟s instructions i.e. isolates were classified as 
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 
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KwaZulu-Natal 
Gauteng 
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resistant if they had a missing wild type band and corresponding mutation band or just 
missing wild type band.  
 
The 41 specimens were grouped according to their discordant patterns shown in Table 3.2. 
Phenotypic INH and RIF resistance were expressed in 29.3% (12/41) of the discordant 
isolates classifying them as MDR-TB isolates. Genotypically, 17.1% (7/41) were grouped as 
MDR-TB isolates. Of the 12 specimens defined as MDR on phenotypic testing (Groups 2, 3 
and 8), genotypic testing missed the INH resistance on 6 isolates,  showed susceptibility to 
both RIF and INH on 1 isolate and missed RIF resistance on another 5 isolates.  Seven 
isolates detected as MDR-TB on genotypic testing (group 7) were RIF susceptible on 
phenotypic DST.  
 
Twenty-three of 41 (56.1%) isolates with phenotypic INH resistance were classified as 
susceptible to INH on genotypic testing (Groups 1-4). Seven isolates with phenotypic RIF 
resistance were susceptible to RIF on genotypic testing (groups 3, 5, 8) Genotypic resistance 
to RIF were identified in 36.6% (15/41) of isolates (Groups 4, 6, 7) which was not expressed 
phenotypically.  All 12 isolates identified as INH resistant genotypically (group 7 and 8) were 
confirmed on phenotypic testing. 
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Table 3.2 Types of INH and RIF discordant groups between MGIT and Hain LPA DST in M. 
tuberculosis isolates 
Group No. of Isolates 
MGIT LPA 
Type of Discordance INH RIF INH RIF 
1 13 R S S S RS-SS 
2 6 R R S R RR-SR 
3 1 R R S S RR-SS 
4 3 R S S R RS-SR 
5 1 S R S S SR-SS 
6 5 S S S R SS-SR 
7 7 R S R R RS-RR 
8 5 R R R S RR-RS 
S, sensitive; R, resistance 
 
3.1.3 Genes involved in resistance to INH and RIF as classified by the Hain LPA. 
 
In 53.3% (8/15) of the RIF resistant strains identified by the Hain LPA, a missing WT 8 in 
the rpoB RRDR region covering base pairs 530-533 was responsible for the conferred 
resistance with only 50% (4/8) detecting the corresponding mutation 3. Missing WT 3 and 4 
in 26.6% (4/15) of strains were detected without any corresponding mutations. Two strains 
with missing WT 2 and one strain missing WT 4 showed no corresponding mutations on the 
Hain LPA. In summary, 11/15 isolates determined as discordant RIF resistance on genotypic 
testing were due to a missing wildtype with no corresponding mutation. Of these 9/11 were 
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phenotypically susceptible while all 4 specimens that had a missing wildtype and a mutation 
were confirmed as phenotypically resistant.  
 
INH resistance was detected mostly in the katG gene, 66.7% (8/12) of the strains. The 
omission of the WT and the presence of mutation 1 were seen in seven out of the eight strains 
with 1 strain having mutation 2 instead. There was one strain in which the WT was present as 
well as mutation 1 in the katG gene suggesting a mixed infection. In the inhA gene all four 
strains had WT 1 missing with mutation 1 present. None of the INH resistant strains had 
resistance detected simultaneously in the katG and inhA gene regions. 
 
Eighty-five (6/7) percent of MDR-TB isolates (group 7) exhibited a katG315 mutation. The 
katG315 mutation is therefore strongly associated with MDR-TB strains.  Of the 12 
specimens (groups 2, 3 and 8) classified as MDR-TB on conventional DST 2 showed katG 
mutation, 3 showed inhA mutation and 7 failed to show INH resistance genotypically. 
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Table 3.3 Pattern of gene mutations detected by the Hain LPA in INH and RIF discordant    
M. tuberculosis strains 
 
Group # 
katG 
missing 
WT 
Mutation 
inhA 
missing 
WT 
Mutation rpoB missing WT Mutation 
1 (RS-SS) 
n=13 
              
2 (RR-SR) 
n=6 
4         8 (530-533) 3 (S531L) 
1 
    
8 (530-533) 
 
1         2 (510-513)   
3 (RR-SS) 
n=1 
1             
4 (RS-SR) 
n=3 
2         2 (510-513)   
1         
3 (513-517) + 4 (516-
519) 
  
5 (SR-SS) 
n=1 
1             
6 (SS-SR) 
n=5 
5         2 (510-513)   
7 (RS-RR) 
n=7 
2 1 (315) 1 (S315T1) 
  
3 (513-517) + 4 (516-
519)  
 
1 1 (315) 2 (S315T2) 
  
3 (513-517) + 4 (516-
519)  
 
2 1 (315) 1 (S315T1) 
  
8 (530-533) 
 
 
1 
  
1 (-15/-16) 1 (C15T) 8 (530-533) 
 
  1 1 (315) 1 (S315T1)     4 (516-519)   
8 (RR-RS) 
n=5 
3 
  
1 (-15/-16) 1 (C15T) 
  
 
1 1 (315) 1 (S315T1) 
    
  1   1 (S315T1)         
 
3.1.4 MIC determination to the anti-tuberculosis drugs INH and RIF 
 
Colorimetric MIC results for all 41 of the clinical isolates were available by the 9
th
 day of 
incubation (Figure 3.3). The MIC result ranges of each discordant group obtained are shown 
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in Table 3.5.  Cut off /Breakpoint for conventional phenotypic DST on MGIT is 1.25 µg/ml 
for RIF and 0.1 µg/ml for INH. The MIC drug dilution series used is shown in Table 3.4. 
 
 
Figure 3.3 Microtitre plate showing results from Alamar blue assay 
 
Table 3.4 MIC dilution series used for both RIF and INH concentrations 
W1 
Water 
W2 
10.0 
µg/ml 
W3 
5.0 
µg/ml 
W4 
2.5 
µg/ml 
W5 
1.25 
µg/ml 
W6 
0.6 
µg/ml 
W7 
0.3 
µg/ml 
W8 
0.15 
µg/ml 
W9 
0.07 
µg/ml 
W10 
0.03 
µg/ml 
W11 
Contr
ol 
W12 
Water 
No growth 
Water 
Controls 
Growth 
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Table 3.5 Ranges of MIC‟s to INH and RIF for the different discordant groups 
 
Group 
No. of 
Specimens 
MGIT LPA  
INH RIF INH RIF 
INH MIC 
(0.1µg/ml) 
RIF MIC 
 
(1.25µg/ml) 
1 13 R S S S 0.07-1.25 0.03-1.25 
2 6 R R S R 0.6-1.25 1.25-2.5 
3 1 R R S S 1.25 2.5 
4 3 R S S R 0.15-0.6 0.6-1.25 
5 1 S R S S 0.6 1.25 
6 5 S S S R 0.03-0.6 0.03-2.5 
7 7 R S R R 0.03-5 0.6-5 
8 5 R R R S 0.07-2.5 0.03-1.25 
 
Twenty three of 41 isolates with phenotypic INH resistance were classified as susceptible to 
INH on genotypic testing (Groups 1-4). The MIC‟s for 22/23 of these isolates supports the 
phenotypic resistant profile with one susceptible isolate having a MIC concentration one 
dilution away from breakpoint. Seven of 13 isolates with phenotypic RIF resistance were 
susceptible to RIF on genotypic testing (groups 3, 5, 8) with four isolates having MIC‟s as 
per phenotypic result, two with MICs one dilution away from breakpoint and one isolate with 
a susceptible MIC 5 dilutions below breakpoint. Genotypic resistance to RIF were identified 
in 15/41 of isolates (Groups 4, 6, 7) which was not expressed phenotypically with 11/15 
isolates having MIC values as per genotypic resistance, 3/15 isolates with MIC values one 
dilution from breakpoint and, only 1/15 isolate having a MIC value 5 dilutions away from 
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breakpoint.  All 12 isolates identified as INH resistant genotypically (group 7 and 8) were 
confirmed on phenotypic testing with corresponding MIC‟s. Interestingly, in group 7 which is 
MDR genotypically, with genotypic RIF resistance expressed as phenotypically susceptible, 
had MIC values in keeping with the genotypic result.   
 
The MIC ranges for group 1, classified as genotypically susceptible to INH and RIF by the 
Hain LPA, phenotypic INH resistance was concordant to the MIC values for 12/13 with 1/13 
isolate expressing susceptibility 5 dilutions away from breakpoint Table 3.6. For RIF in this 
group, the phenotypic and genotypic results were concordant with MIC values expressing 
susceptibility in 10/13 isolates with 3/13 isolates resistant to RIF by MIC testing. In group 2, 
the INH MIC‟s correlate to the phenotypic result of resistant in all isolates while 4 of the RIF 
resistance findings shown on the LPA were confirmed by MIC determination with 2 isolates 
showing borderline resistance of 1.25µg/ml (Table 3.6). Group 3, MIC results for both INH 
and RIF are associated with the resistance results observed phenotypically. In group 7 (Hain 
LPA MDR), the MIC for RIF confirm the genotypic resistance expressed on the LPA (6/7) 
with only 1 isolate having a susceptible MIC to RIF in the group (Table 3.6).   
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Table 3.6 MIC results obtained for all 41 INH/RIF discordant isolates  
Group MGIT INH MGIT RIF LPA INH LPA RIF MIC INH MIC RIF 
1 
R S S S 0.15 0.03 
R S S S 0.3 0.6 
R S S S 1.25 0.3 
R S S S 0.6 1.25 
R S S S 1.25 0.6 
R S S S 1.25 0.6 
R S S S 1.25 0.15 
R S S S 0.6 0.03 
R S S S 1.25 0.6 
R S S S 1.25 1.25 
R S S S 0.07 0.15 
R S S S 0.15 2.5 
R S S S 1.25 0.15 
2 
R R S R 1.25 2.5 
R R S R 0.6 2.5 
R R S R 1.25 2.5 
R R S R 1.25 1.25 
R R S R 0.6 1.25 
R R S R 1.25 2.5 
3 R R S S 1.25 2.5 
4 
R S S R 0.15 0.6 
R S S R 0.6 0.6 
R S S R 0.6 1.25 
5 S R S S 0.6 1.25 
6 
S S S R 0.07 1.25 
S S S R 0.07 2.5 
S S S R 0.6 2.5 
S S S R 0.15 1.25 
S S S R 0.03 0.03 
7 
R S R R 0.15 2.5 
R S R R 1.25 0.6 
R S R R 2.5 1.25 
R S R R 1.25 5 
R S R R 1.25 2.5 
R S R R 0.3 1.25 
R S R R 5 2.5 
8 
R R R S 0.15 1.25 
R R R S 1.25 0.6 
R R R S 1.25 1.25 
R R R S 2.5 0.6 
R R R S 0.6 0.03 
      S, sensitive; R, resistance 
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3.1.5 Characterisation of the discordant isolates by spoligotyping 
 
All 41 INH/RIF discordant isolates were characterised by spoligotyping and grouped into 17 
previously identified strain families and 8 families which were not in the international 
Spoligotype database (SpolD4B), Table 3.7. The five major families amongst the phenotypic 
and genotypic discordant isolates were; East Asian Beijing, Latin America and Mediterranean 
(LAM), X, T and S. The other strain families in the international spoligotype database and the 
distribution of strains across provinces are shown in Table 3.7. There were 8 isolates from 
previously unreported families that were termed orphans (Figure 3.4). Of the 8 orphan 
isolates, 3 belonged to a mixed lineage, 2 belonged to a low copy number clade (LCC), and 1 
belonged to the LAM lineage. Two orphan isolates were not assigned to any families (Figure 
3.4).    
 
The LAM lineage was the most frequent, making up 21.9% (9/41) of the isolates, whereas 
EAI was least frequent, making up 2.4% (1/41). Seven of the orphan isolates could not be 
assigned to any of the lineages previously described (Table 3.7). In the Hain LPA RIF 
resistant isolates, lineage X was predominant (7/21), whereas in the phenotypic RIF resistant 
isolates the LAM lineage was most frequently represented (3/13). In the INH phenotypic and 
genotypic concordant isolates, majority of the isolates were from the X and LAM lineages. In 
the discordant INH groups all lineages were present. 
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Table 3.7 The different lineages observed among the 41 discordant isolates spoligotyped 
across four South African provinces 
 
Spoligo Family Frequency (n) Percent 
BEIJING 7 17.07 
Western Cape 7  
   
LAM 9 21.95 
Western Cape 7  
Gauteng 1  
Northern Cape 1  
   
T 4 9.76 
Western Cape 3  
Northern Cape 1  
   
EAI 1 2.44 
Gauteng 1  
   
S 3 7.32 
Western Cape 1  
Gauteng 1  
KwaZulu-Natal 1  
   
U 2 4.88 
Western Cape 2  
   
X 8 19.51 
Western Cape 7  
Northern Cape 1  
   
Unknown spoligotype 7 17.07 
Western Cape 7   
 41 100.00 
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No. Pattern SIT
*
  Family Octal value 
1  33 LAM3 776177607760771 
2  1 BEIJING 000000000003771 
3  Orphan F9 677777606060771 
4  Orphan MIX 776177607763771 
5  1 BEIJING 000000000003771 
6  280 T1 770000777760771 
7  1241 U 777777607700771 
8  237 U  777777777700000 
9  1 BEIJING 000000000003771 
10  33 LAM3 776177607760771 
11  92 X3 700076777760771 
12  92 X3 700076777760771 
13  33 LAM3 776177607760771 
14  Orphan Undesignated 777774777760771 
15  33 LAM3 776177607760771 
16  159 T1  777740017760771 
17  92 X3 700076777760771 
18  92 X3 700076777760771 
19  Orphan MIX 776177607763771 
20  Orphan Undesignated 760721047700771 
21  48 EAI1 777777777413731 
22  1 BEIJING 000000000003771 
23  789 S 676377777760771 
24  1 BEIJING 000000000003771 
25  92 X3 700076777760771 
26  Orphan LCC 077776775760731 
27  1222 LAM9 770177607760771 
28  34 S 776377777760771 
29  92 X3 700076777760771 
30  33 LAM3 776177607760771 
31  1329 X1 777776777560771 
32  92 X3 700076777760771 
33  1 BEIJING 000000000003771 
34  154 T1 757777777760771 
35  33 LAM3 776177607760771 
36  Orphan LCC 300076777760771 
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 *SIT: Standard international type 
Figure 3.4 Spoligotype patterns of the 41 INH/RIF discordant M.tuberculosis isolates used in 
the study.  
 
3.1.6 Sequencing analysis of the gene regions which confer resistance to the anti-
tuberculosis drugs rifampicin and isoniazid 
  
3.1.6.1 The rpoB gene region 
 
Since the majority of strains resistant to RIF harbour mutations within the RRDR of rpoB, 
this region and flanking sequence were analysed in this study. Twenty-two phenotypic and 
genotypic rifampicin discordant isolates were sequenced for mutations associated with the 
rpoB gene region. Among the isolates analysed, 59.1% (13/22) had mutations in rpoB (Table 
3.8). The most frequently observed mutation was found in codon 458 (CTG to CCG, 
Leu458Pro), observed in 7 of the 22 (31.8%) of isolates. Four isolates had a Leu436Pro (CTG 
to CCG) mutation with two isolates having mutations in codon 441 (GAC to GGC, 
Asp441Gly) (Table 3.8). None of these mutations are present on the Hain LPA. Twelve of the 
13 isolates with novel mutations were classified as RIF resistant on Hain LPA based on 
missing WT (no mutation detected). All 12 were phenotypically susceptible. One isolate was 
classified as susceptible on Hain LPA and was phenotypically RIF resistant. 
37  1333 S 776370001760771 
38  1 BEIJING 000000000003771 
39  Orphan MIX 776177607763771 
40  33 LAM3 776177607760771 
41  44 T5 777777757760771 
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In the isolates which were phenotypically susceptible but genotypically resistant to rifampicin 
(Groups 4, 6, 7), 73.3% (11/15) displayed mutations correlating to the genotypic LPA 
resistance expressed. Although the other 4 isolates in this group had resistant MIC values, no 
mutations were observed in the rpoB gene region sequenced for RIF. In the 7 isolates which 
were phenotypically resistant but genotypically classified susceptible (Groups 3, 5, 8), 28.6% 
(2/7) showed a mutation present in codon 458 (CTG to CCG, Leu458Pro) which is not 
present on the Hain LPA and has not been previously reported (Table 3.9).  
 
The two isolates which had a missing WT 8 without a corresponding mutation showed a 
mutation/mutations in codon 441 on sequencing which is not represented on the Hain LPA. 
The MIC of these two isolates‟ showed 1 resistant strain (2.5 µg/ml) and the other with 
borderline (1.25 µg/ml) resistance. In the isolates which displayed a missing WT 2 with no 
matching mutation on the LPA, mutation in codon 436 was observed in 57.1% (4/7) of the 
isolates with MICs confirming resistance in 3 isolates. Mutation in codon 458 was associated 
with 80% (4/5) of isolates with no WT 3 and/or WT 4 present (Table 3.9) without an 
associated mutation band. The MICs for isolates with a codon 458 mutation showed 2 
resistant and 2 susceptible isolates. Of the 7 isolates with rpoB gene mutation 458, 6/7 were 
genotypically resistant but susceptible on phenotypic DST and one isolate was genotypically 
susceptible but phenotypically resistant confirmed with a borderline MIC value of 1.25 
µg/ml. 
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Table 3.8 Frequency of mutations in the rpoB gene region detected 
 
 
Table 3.9 Sequencing results of the rpoB gene region in genotypic and phenotypic discordant 
samples 
  
Group 
MGIT 
RIF 
LPA 
RIF LPA rpoB profile 
MIC 
RIF 
Location of 
mutations 
Nucleotide 
changes 
Amino acid 
changes 
3 R S NC 2.5    
4 
S R WT2 MIS NO MUT 0.6 Codon 458 CTG to CCG Leu (L) to Pro (P) 
S R WT3 + 4 MIS NO MUT 0.6 Codon 458 CTG to CCG Leu (L) to Pro (P) 
S R WT2 MIS NO MUT 1.25 Codon 436 CTG to CCG Leu (L) to Pro (P) 
5 R S NC 1.25 Codon 458 CTG to CCG Leu (L) to Pro (P) 
6 
S R WT2 MIS NO MUT 1.25 Codon 436 CTG to CCG Leu (L) to Pro (P) 
S R WT2 MIS NO MUT 2.5 Codon 436 CTG to CCG Leu (L) to Pro (P) 
S R WT2 MIS NO MUT 2.5    
S R WT2 MIS NO MUT 1.25    
S R WT2 MIS NO MUT 0.03 Codon 436 CTG to CCG Leu (L) to Pro (P) 
7 
S R WT8 MIS NO MUT 2.5 Codon 441 GAC to GGC Asp (D) to Gly (G) 
S R WT4 MIS NO MUT 0.6 Codon 458 CTG to CCG Leu (L) to Pro (P) 
S R WT3 + 4 MIS NO MUT 1.25    
Location of mutations Nucleotide changes Amino acid changes No. (%) of strains 
n = 22 
Codon 436 CTG to CCG Leu (L) to Pro (P) 4 (18.2) 
Codon 441 GAC to GGC Asp (D) to Gly (G) 2 (9.0) 
Codon 458 CTG to CCG Leu (L) to Pro (P) 7 (31.8) 
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S R WT8 MIS + NO MUT 5    
S R WT3 + 4 MIS NO MUT 2.5 Codon 458 CTG to CCG Leu (L) to Pro (P) 
S R WT8 MIS NO MUT 1.25 Codon 441 GAC to GGC Asp (D) to Gly (G) 
S R WT3 + 4 MIS NO MUT 2.5 Codon 458 CTG to CCG Leu (L) to Pro (P) 
8 
R S NC 1.25    
R S NC 0.6    
R S NC 1.25 Codon 458 CTG to CCG Leu (L) to Pro (P) 
R S NC 0.6    
R S NC 0.03    
NC- no change 
 
3.1.6.2 The katG and inhA gene region 
 
 
 A total of twenty-three isolates were each sequenced for mutations in the katG and inhA loci. 
All isolates were phenotypically resistant to isoniazid and genotypically susceptible 
according to the Hain LPA. In the katG gene region only four mutations (Table 3.10) were 
detected in codon 213 (GGT to GTT, Gly213Val), codon 232 (CCC to AAA, Pro232Lys), 
codon 254 (AAG to AAC, Lys254Asn) and, in codon 259 (AGC to AAC, Ser359Asn). These 
mutations are not present on the Hain LPA and have not been previously reported to be 
associated with resistance. There were three isolates which had simultaneous mutations in 
inhA and katG in isolates (Table 3.12). The katG315 mutation which is strongly correlated 
with MDR-TB strains (Bolotin et al, 2009) was not observed in any of the discordant isolates. 
The remaining twenty isolates showed no mutations in the analysed region of the katG gene. 
70 
 
Table 3.10 Frequency of mutations in the katG gene locus 
 
Location of 
mutations 
Nucleotide changes Amino acid changes No. (%) of strains 
n = 23 
Codon 213 GGT to GTT Gly (G) to Val (V) 1  (4.3 ) 
Codon 232 CCC to AAA Pro(P) to Lys(K) 1  (4.3) 
Codon 254 AAG to AAC Lys (K) to Asn (N) 1  (4.3) 
Codon 259 AGC to AAC Ser (S) to Asn (N) 1 (4.3) 
 
Among the twenty-three phenotypic isoniazid resistant isolates analysed for mutations in the 
inhA gene region, 47.8% (11/23) of the isolates had mutations in this region. There were 18 
different locations with codon mutations (Table 3.11). The most frequent mutations detected 
in inhA locus was the amino acid change at positions; codon -2 (Thr to Ser), codon -23 (Gly 
to Stop codon), and codon -36 (Ala to Gly), each contributing 17.4% of these mutations. Two 
isolates had a maximum combination of 7 different amino acid changes at various codons 
(Table 3.11) both these isolates were resistant to INH at the 1.5 µg/ml level. Five other 
isolates had combination nucleotide substitutions at other codons. Interestingly mutation in 
codon -22 and -23, gave rise to “stop” codons while mutations in codon -12, -21, -35, -48 did 
not convert into interpretable amino acid changes. As expected none of these discordant 
isolates contained a cytosine-to-thymine transition at the nucleotide positioned 15 bases 
upstream from the start codon which has been reported as one of the most common mutations 
in the inhA promoter region and is represented on the Hain LPA strip. There were no 
mutations present in the inhA promoter region for the other 12 phenotypically resistant 
isolates which were classed as susceptible by the LPA (Table 3.12). 
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Table 3.11 Frequency of mutations in the mabA-inhA promoter gene locus detected 
 
Location of 
mutations 
Nucleotide 
changes 
Amino acid changes No. (%) of strains 
n = 23 
Codon -2 ACT to AGT Thr (T) to Ser (S) 4 (17.4) 
Codon -5 GCC to TGG Ala(A) to TGG (W) 2 (8.7) 
Codon -12 CCA to CTG Pro(P) to Leu (L) 1 (4.3) 
Codon -12 CCA to CCG none 1 (4.3) 
Codon -21 ACC to ACT none 3 (13.0) 
Codon -22 GGA to TGA Gly (G) to Stop codon 3 (13.0) 
Codon -23 GGA to TGA Gly (G) to Stop codon 4 (17.4) 
Codon -24 AAC to AGC Asn (N) to Ser (S) 1 (4.3) 
Codon -30 GCG to GGG Ala (A) to Gly (G) 2 (8.7) 
Codon -31 ATC to TTC Ile (I) to Phe (F) 1 (4.3) 
Codon -33 CAG to TGG Gln (Q) to Trp (W) 1 (4.3) 
Codon -34 CGG to GGG Arg (R) to Gly (G) 2 (8.7) 
Codon -35 CTG to TTG none 1 (4.3) 
Codon -36 GCT to GGT Ala (A) to Gly (G) 4 (17.4) 
Codon -41 AAG to TGG Lys (K) to Trp (W) 1 (4.3) 
Codon -48 GGA to GGG none 1 (4.3) 
Codon -63 ACC to TCC Thr (T) to Ser (S) 2 (8.7) 
Codon -63 ACC to ATC Thr (T) to Ile (I) 1 (4.3) 
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Table 3.12 Sequencing results of inhA and katG gene regions in INH genotypic and 
phenotypic discordant isolates 
 
Group 
MGIT 
INH 
LPA 
INH 
MIC 
INH 
inhA promoter region katG region 
Location of 
mutations  
Nucleotide 
changes Amino acid changes 
Location of 
mutations 
Nucleotide 
changes 
Amino acid 
changes 
1 
R S 0.15 Codon -21 ACC to ACT none    
   Codon -23 GGA to TGA Gly (G) to Stop codon    
   Codon -48 GGA to GGG none    
R S 0.3    Codon 232 CCC to AAA 
Pro(P) to 
Lys(K) 
R S 1.25       
R S 0.6       
R S 1.25 Codon -22 GGA to TGA Gly (G) to Stop codon    
   Codon -23 GGA to TGA Gly (G) to Stop codon    
   Codon -24 AAC to AGC Asn (N) to Ser (S)    
   Codon -30 GCG to GGG Ala (A) to Gly (G)    
   Codon -34 CGG to GGG Arg (R) to Gly (G)    
   Codon -31 ATC to TTC Ile (I) to Phe (F)    
   Codon -36 GCT to GGT Ala (A) to Gly (G)    
R S 1.25 Codon -12 CCA to CTG Pro(P) to Leu (L)    
   Codon -12 CCA to CCG none    
   Codon -21 ACC to ACT none    
   Codon -22 GGA to TGA Gly (G) to Stop codon    
   Codon -23 GGA to TGA Gly (G) to Stop codon    
   Codon -33 CAG to TGG Gln (Q) to Trp (W)    
   Codon -36 GCT to GGT Ala (A) to Gly (G)    
R S 1.25       
R S 0.6       
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R S 1.25       
R S 1.25       
R S 0.07 Codon -2 ACT to AGT Thr (T) to Ser (S) Codon 213 GGT to GTT 
Gly (G) to 
Val (V) 
   Codon -5 GCC to TGG Ala(A) to TGG (W)    
   Codon -36 GCT to GGT Ala (A) to Gly (G)    
R S 0.15 Codon -63 ACC to TCC Thr (T) to Ser (S)    
R S 1.25 Codon -2 ACT to AGT Thr (T) to Ser (S)    
   Codon -5 GCC to TGG Ala(A) to TGG (W)    
2 
R S 1.25       
R S 0.6 Codon -22 GGA to TGA Gly (G) to Stop codon    
   Codon -23 GGA to TGA Gly (G) to Stop codon    
   Codon -30 GCG to GGG Ala (A) to Gly (G)    
   Codon -33 CAG to TGG Gln (Q) to Trp (W)    
   Codon -35 CTG to TTG none    
   Codon -36 GCT to GGT Ala (A) to Gly (G)    
R S 0.6 Codon -2 ACT to AGT Thr (T) to Ser (S)    
R S 1.25       
R S 0.6 Codon -63 ACC to ATC Thr (T) to Ile (I)    
R S 1.25 Codon -21 ACC to ACT none Codon 254 AAG to AAC 
Lys(K) to 
Asn (N) 
   Codon -41 AAG to TGG Lys (K) to Trp (W)    
   Codon -63 ACC to TCC Thr (T) to Ser (S)    
3 R S 1.25 Codon -2 ACT to AGT Thr (T) to Ser (S)    
4 
R S 0.15       
R S 0.6    Codon 259 AGC to AAC 
Ser (K) to 
Asn (N) 
R S 0.6       
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Sequencing analysis only detected mutations, either in katG and/or in inhA for 56.2% (13/23) 
of the phenotypically resistant discordant isolates. Interestingly neither katG nor inhA genetic 
alterations were detected in 10 (43.4%) clinical isolates which were phenotypically resistant 
with corresponding resistant MIC values.  
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Chapter 4 
 
4.1 Discussion 
 
The re-emergence of TB and drug-resistant isolates of M. tuberculosis poses a severe threat 
to the global control of TB (Evans et al, 2009), especially in Asia and Africa (Stavrum et al, 
2009). Rapid, reliable and cost effective new drug susceptibility diagnostic tools are required 
urgently to control the TB and MDR-TB epidemics (Luo et al, 2010). Molecular methods can 
provide accurate and rapid drug susceptibility results which are critical to ensure that patients 
receive effective treatment and become non-infectious (Campbell et al, 2010). However,   
regional specific information on the type and frequency of drug resistance-conferring 
mutations is also required (Luo et al, 2010). Our study adds to the body of knowledge and 
specifically describes a novel set of mutations observed from phenotypic and genotypic 
discordant isolates.  
 
The results from this study demonstrates the utility of detection of mutations associated with 
drug resistance to rapidly and accurately determine the drug susceptibility of M. tuberculosis 
complex isolates as compared to conventional phenotypic methods but also highlights some 
limitations of the methodology.  
 
The isolates used in this study were distributed across Western Cape, Northern Cape, 
Gauteng and KwaZulu-Natal provinces of South Africa. The rate of discordant isolates 
identified in the larger Demonstration project from Western Cape, Northern Cape, Gauteng 
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and KwaZulu-Natal were 9.2%, 4.7%, 2.6% and 3.4% respectively. The proportion of INH 
and/or RIF phenotypic and genotypic discordant isolates varied with the majority of the 
isolates from the country coming from the Western Cape, 82.9% with the lowest number of 
isolates (2.4%) coming from KwaZulu-Natal.   
 
Among the isolates, phenotypic MDR-TB was expressed in 29.3%, genotypically only 17.1% 
of the same study set was classified as MDR-TB isolate by the Hain LPA. While all INH 
resistance detected genotypically was confirmed phenotypically, phenotypic INH resistance 
was not detected by the Hain in 23 (56.1%) of isolates. In 22 of these, the MIC results 
confirmed resistance. Similarly, as discussed below, sequencing analysis only detected 
mutations, either in katG and/or in inhA for 56.2% (13/23) of the phenotypically resistant 
discordant isolates. These results reflect the complexity of the genetic basis of INH resistance 
compared with RIF. 
 
Many laboratories would do phenotypic INH DST if RIF monoresistance is detected by the 
Hain LPA and in SA according to current NTCP guidelines both RIF monoresistance and 
MDR would be treated as MDR-TB. However, false classification of MDR-TB as RIF 
monoresistance could have implications for surveillance especially as the Western Cape have 
recently shown a trend of increasing RIF monoresistance. Accurate discrimination between 
MDR and RIF monoresistance is also important as utilisation of many molecular tests is 
based on the assumption that RIF resistance can be used as a proxy for MDR-TB. 
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Results for RIF were less clear cut. Seven of 13 isolates with phenotypic RIF resistance were 
susceptible to RIF on genotypic testing with four isolates having MIC‟s as per phenotypic 
result. Three of the 4 had MICs at breakpoint concentration and the other 1 dilution above 
breakpoint. These borderline resistance/susceptible observations in isolates have also been 
reported by van Deun et al, as the reason for discordant phenotypic and genotypic DST 
results (van Deun et al, 2009). Genotypic RIF resistance in 15 isolates (36.6%) was not 
expressed phenotypically and 11/15 MIC results confirmed genotypic resistance. This 
included 6/7 isolates classified as MDR-TB genotypically and INH-monoresistant on 
phenotypic DST. Furthermore 11/15 isolates determined as RIF resistance on genotypic 
testing demonstrated a missing wildtype with no corresponding mutation. Of these, 9/11 were 
phenotypically susceptible. However, all 4 specimens that had a missing wildtype and a 
mutation were confirmed as phenotypically resistant. This suggests that RIF resistance 
diagnosed on LPA due to missing WT only should be confirmed on phenotypic DST. 
 
DNA sequencing is still the most sensitive molecular diagnostic tool for identification of 
mutations. The study shows the advantage of sequencing over DNA probe based assays to 
detect a limited set of specific mutations, since several mutations associated with drug 
resistance identified in this study have not been previously reported. Hain LPA probes of the 
RRDR do not cover these mutations and further research should be performed as these 
mutations may have important ramifications for new probe based genotypic diagnostic tools 
for the detection of RIF resistance. With the use of molecular diagnostics for the rapid 
detection of MDR-TB there is some concern regarding isolates which are not detected by the 
selection of probes on the Hain LPA. Patients infected with these strains will not receive 
correct treatment and may go on to develop further resistance conferring mutations, 
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contributing to the pool of resistance. For this reason in routine practice currently in SA, 
many laboratories will do phenotypic DST if Hain LPA shows monoresistance. A study by 
van Deun et al, 2009 has reported that conventional RIF DSTs can yield highly discordant 
results even among proficient laboratories and therefore the mutations found and reported in 
this study should further be investigated.  
 
The molecular mechanism of resistance to RIF is well understood and documented in 
comparison to the resistance mechanisms of other anti-tuberculosis drugs. It has been well 
established that mutations within the RRDR region of the rpoB gene confer more than 95% 
of resistance to RIF. The commonest mutations within the RRDR region are Ser531Leu, 
His526Tyr, and Asp516Val (Campbell et al, 2011). Amongst RIF susceptibility discordant 
strains in a study previously reported, predominant mutations recorded in the rpoB gene were 
Leu511Pro, Asp516Tyr, His526leu/Ser, and Leu533Pro (van Deun et al, 2009).   
 
On sequencing, 13 of the 22 (59.1%) RIF- resistant isolates demonstrated mutations in the 
rpoB region. However, none of the previously reported mutations from SA (Green et al, 
2008; Evans et al, 2009) were detected among this discordant group. In this study, the 
sequenced strains harboured only 3 types of mutations, Leu458Pro, Leu436Pro, and 
Asp441Gly, in eleven genotypically (Hain LPA) RIF resistant and two  genotypically RIF 
susceptible isolates. Despite the mutations resulting in an amino acid change, 10 of the 11 
isolates harbouring these mutations were phenotypically susceptible. On MIC testing, 9/13 
were resistant.  
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Mutation Asp441Gly in two isolates were associated with a missing WT8 on the Hain LPA 
with no corresponding mutation detected. One isolate with this mutation was resistant with 
the other isolate expressing borderline resistance to RIF. Mutation Leu436Pro was present in 
isolates with a missing WT2 and no mutation bands present with MIC‟s favouring the 
genotypic resistance. Resistant isolates missing WT3 and/or WT4 without one of the probe 
mutations had mutation Leu458Pro. Of these isolates according to the MIC‟s, 50% were 
resistant and the other 50% had MIC‟s of one dilution away from the breakpoint.  
 
These mutations 441, 436 and, 458 are not represented on the Hain LPA strips and would be 
missed at diagnosis or detected on the basis of missing wild type only.  Further studies are 
required to characterize the roles of these mutations in RIF resistance. With the increased use 
of genotypic methods to diagnose RIF resistance, these mutations may be more frequently 
observed, and subsequently, their clinical and epidemiological significance may be better 
understood.  
 
Although INH has been a key component of tuberculosis chemotherapeutic regimens for 
several decades, the mode of action of INH though extensively investigated, remains 
incompletely understood (Rouse et al, 1995; Campbell et al, 2011). INH is classified as a 
prodrug which is activated by the catalase-peroxidase enzyme which is coded for by katG. 
Mutations within katG, particularly at codon 315, can result in the loss of catalase activity 
giving rise INH resistance. The target of activated INH is enoyl-acyl carrier protein reductase 
(InhA). The increased expression of inhA as a result of promoter mutations leads to the 
resistance to isoniazid through a titration mechanism. In this study we sequenced a region of 
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katG which includes codon 315 and the inhA promoter region because it has been well 
documented that most INH-resistant isolates which together account for approximately 65-
75% of resistant strains (Ramaswamy et al, 1998), contain mutations in one or both of these 
regions. 
 
There are several different loci that are known to be involved in resistance but the most 
frequent resistance-conferring mutations are detected in katG and less commonly in the inhA 
promoter region (Luo et al, 2010; Bolotin et al, 2009). Mutations in codon 315 of katG are 
known to only introduce a slight fitness cost to the bacterium (Luo et al, 2010; Bolotin et al, 
2009) and are a proven mechanism of INH resistance (Campbell, 2011). In our study, 85.7% 
of phenotypic MDR-TB isolates and 40% of the isoniazid mono-resistant had mutations in 
codon 315 of the katG by Hain LPA but unfortunately this could not be confirmed by 
sequencing as these isolates were concordant and excluded from further study investigations. 
This is in agreement with previous studies in which mutations in codon 315 of katG is 
significantly more common in MDR isolates (van Doorn et al, 2006; Valvatne et al, 2009). 
Among the isolates sequenced in our study, only four of twenty three isolates had a mutation 
in katG, at codon Gly213Val, Pro232Lys, Lys254Asn, and Ser259Asn. None of the 
discordant isolates had the katG315 mutation which is strongly correlated with MDR-TB 
strains (Bolotin et al, 2009).  
 
Eleven (47.8%) of twenty-three phenotypic isoniazid-resistant isolates sequenced had 
mutations in the inhA promoter region. There were eighteen different codon mutations and 
interestingly, 7 isolates had combinations of nucleotide changes at various codons. Mutations 
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at codon -22 and -23 strangely gave rise to „stop‟ codons and nucleotide mutation at -12, -21, 
-35, and -48 did not translate into interpretable amino acid changes. None of the discordant 
isolates in this study had the common C-15T mutation associated with the inhA promoter 
region. Sequencing was only able to detect mutations in 56.2% of phenotypically resistant 
isoniazid discordant isolates with corresponding resistant MIC values. Our failure to identify 
mutations in the katG and inhA promoter regions sequenced in these discordant isolates 
confirms that additional mechanisms are responsible for INH resistance. Our study has shown 
that certain regulatory defects that affect inhA promoter region does exist with the interesting 
„stop‟ codon transcription and the un-interpretable amino-acid changes, but further 
investigations are required to determine their role in INH resistance. 
 
The distribution of M. tuberculosis genotypes in some areas of SA has been previously 
described (Chihota et al, 2012; Stavrum et al, 2009); however, apart from this study, there 
are, to our knowledge no studies which have mapped the distribution of RIF and/or INH 
phenotypic and genotypic discordant M. tuberculosis genotypes across SA.   
 
In this study, 41 RIF and/or INH phenotypic and genotypic discordant isolates were 
genotyped by spoligotyping. Eighty-three percent of the spoligopatterns were reported in 
SpolDB4 (Brudey et al, 2006) and were assigned seven different lineages. Previous studies 
looking at the different genotypes in South Africa have reported the Beijing/W-like and the 
T-lineage to be the predominant lineages among drug-resistant isolates in the Western Cape 
(Stavrum et al, 2009; Streicher et al, 2003). Our findings show that the four predominant 
families found in South Africa amongst discordant isolates are the LAM, T, X and, S which 
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is in agreement with findings reported by Chihota et al. (Chihota et al, 2012). In this study, 
the most common lineage was the LAM lineage which made up 21.9% of the discordant 
isolates. The LAM lineage can be split into sublineages LAM1 to LAM11 with the 
sublineage LAM3 being the most frequently associated with phenotypic RIF resistant isolates 
(23%) in this study. Isolates from the Beijing lineage have been the cause of large outbreaks 
of TB worldwide and have shown an association with MDR-TB (Toungossova et al, 2002; 
Stavrum et al, 2009). The Beijing lineage, in our study, accounted for 17.0% of the total 
number of isolates tested and was the third most prevalent genotype after the LAM and X 
lineages. In our study, five out of seven genotypically INH susceptible isolates according to 
the Hain LPA and phenotypically resistant are of the X3 lineage which is in concordance 
with the findings reported from Western Cape which had suggested that the X3 lineage may 
represent dissemination of a dominant isoniazid-monoresistant clone with a unique isoniazid 
resistance determinant. (Evans et al, 2009). Furthermore, in the INH concordant group 
(genotypically and phenotypically INH resistant) the majority of the isolates were from the 
X3 and LAM lineages while among the discordant groups all lineages were present. This 
study shows that phenotypic and genotypic RIF and/or INH discordant isolates are not linked 
to a single strain lineage. The numerous spoligotype patterns observed in this study suggests 
there is a high diversity of circulating M. tuberculosis strains in South Africa (Chihota et al, 
2012) with no one single genotype dominating the TB epidemic in this area.      
 
4.2 Limitations 
 
One of the challenges with this study was obtaining a good yield of pure cultures for the 
phenotypic DST, as the culture collection dated from 2007-2008 period. Even though isolates 
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were cultured on Lowenstein Jensen (L-J) solid media following NaOH-NALC 
decontamination as well as plating out contaminated isolates for single pure colonies on L-J 
plates, we were unable to obtain pure colonies from the contaminated isolates. Failure to 
grow and persistent contamination in isolates resulted in their exclusion, therefore decreasing 
the overall number of discordant isolates available for the study. 
 
Another problem was the small number of discordant cultures available for the study which is 
not adequately representative of the overall discordance in the main national study. This was 
due to some laboratories not having storage space and discarded cultures from the culture 
collection and there was some loss of viability of the cultures when obtained from the various 
provinces.  
Gene sequencing was only performed on the genes represented on the LPA (i.e. rpoB, katG 
and inhA). In this study, resistance resulting from mutations in other genes known to be 
associated with drug resistance were not investigated. The sequencing of the genes was 
limited because of budget availability. Meaningful analysis of the genotyping is limited by 
the small sample numbers in this study. 
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Chapter 5 
 
5 Conclusion 
 
While several studies have been published on the frequency of LPA mutations in different 
regions (Barnard et al, 2008; Green et al, 2008), this is the first study from South Africa that 
describes the character and distribution of mutations in genes conferring rifampicin and 
isoniazid resistance specifically in strains with discordant phenotypic and genotypic drug 
susceptibility patterns. 
 
The results from this study illustrate that the geographical distribution of mutations resulting 
in drug resistance in M.tuberculosis in SA is different from that reported from other parts of 
the world. Although there is a high level of agreement between genotypic and phenotypic 
data reported, this study highlights the need for ongoing investigations in SA of the resistance 
mechanisms involving anti-tuberculosis drugs. In this study, three new previously unreported 
mutations in the rpoB gene region have been identified and their association with the Hain 
LPA described, further research into these mutations is required for a better understanding 
and their role in drug resistance. The limited detection of mutations in the katG and inhA 
genes and the failure to detect commonly associated and widely reported mutations in these 
gene regions in this study indicate that other known gene regions associated with INH 
resistance should be investigated to better understand the mechanisms responsible for the 
phenotypic resistance expressed with corresponding MICs. The large number of different 
spoligotype patterns observed in this study indicates that there is a high diversity of 
circulating M. tuberculosis strains in SA.    
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Detailed knowledge of the frequency distribution of resistance-associated mutations and 
associated MICs in different regions of SA could facilitate understanding of the limitations of 
current molecular tests and inform testing algorithms. In addition, this information, together 
with identification of novel resistance mechanisms, could facilitate the development of 
customised testing going forward.  Better understanding of the MICs associated with 
molecular changes could assist with decisions on inclusion of drugs with pharmacokinetics 
falling within the therapeutic range, into treatment regimens. Lastly, the relationships 
between molecular resistance, strain fitness and virulence remain to be investigated.  
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